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Abstract 
The extracellular matrix (ECM) protein fibronectin (FN) is a remarkably 
multifaceted molecule, including numerous fibronectin type III (FNIII) repeats carrying 
out different functions, which despite being extensively studied for over thirty years 
still presents certain functions that remain incompletely elucidated. The alternatively 
spliced FN variant containing the extra domain A (FNIII EDA), located between FNIII 11 
and FNIII 12, is expressed in sites of injury, chronic inflammation, and solid tumors. 
Although its function is not well understood, FNIII EDA is known to agonize Toll-like 
receptor 4 (TLR4) and appears to be involved in the progression of different skin 
diseases while studies also suggest that FNIII EDA is involved in tissue repair. The aim 
of this thesis is thus to better understand some of the immunological and regenerative 
functions of FNIII EDA and to translate these findings to develop new vaccination 
strategies based on endogenous proteins. 
One important task in vaccinology is to develop delivery strategies by which to 
present antigen, along TLR agonists, so as to induce a desirable adaptive immune 
response. The use of TLR agonists is associated with sometimes severe constraints and 
concerns about safety, causing inflammatory responses. Thus, the development of safe 
and effective vaccines with fewer side effects is a strong need and requires the 
development of new adjuvants with a correct balance between a strong activation of 
the immune system and a low toxicity for the patient. 
Here, by producing various FN fragments containing FNIII EDA, we show that the 
immunological activity of FNIII EDA depends on its local intramolecular context within 
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the FN chain. N-terminal extension of the isolated FNIII EDA with its neighboring FNIII 
repeats enhanced its activity in agonizing TLR4, while C-terminal extension abrogated 
it. In addition, we reveal that an elastase 2 cleavage site is present between FNIII EDA 
and FNIII 12. Moreover, as FNIII EDA is naturally present within the ECM, we 
incorporated FNIII EDA bound in a fibrin matrix to mimic the in vivo situation and create 
an adjuvant-rich microenvironment. Such matrices were shown to induce functional 
cytotoxic CD8+ T cell responses in two murine cancer models. 
Furthermore, combinations of specific TLR-agonists have the ability to synergize 
to induce immune responses that are greater than the sum of their individual effect. 
Hence, we demonstrate that combination of the TLR9 agonist CpG with FNIII EDA 
synergizes to induce an efficient immune response while keeping the dose of the toxic 
CpG at a minimum. Here, the combination of both adjuvants induced a potent immune 
response sufficient to slow down tumor growth in a murine tumor model as well as to 
break immune tolerance to eradicate circulating hepatitis B virus (HBV) in a transgenic 
HBV mouse model.  
Finally, in the last part of this thesis we revealed that FNIII EDA is a growth factor 
binding domain of FN, with a strong affinity for the platelet-derived growth factor-AA 
(PDGF-AA). We also demonstrated that FNIII EDA and PDGF-AA have together the 
ability to enhance fibroblasts proliferation and differentiation into myofibroblasts. In 
addition, we explored the effects of fibrin matrices functionalized with variants of FNIII 
EDA on wound closure. 
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Résumé  
La Fibronectine (FN) est une protéine multifonctionnelle de la matrice 
extracellulaire (ECM), incluant de nombreux domaines de type III (FNIII) occupants des 
fonctions différentes. Bien qu’ayant été étudiée depuis plus de trente ans, la FN 
présente encore des fonctions qui restent incomplètement élucidées. L’épissage 
alternatif de la FN contenant l’extra domain A (FNIII EDA), placé entre FNIII 11 et FNIII 
12, est exprimé sur les sites de blessures, d’inflammations chroniques et dans les 
tumeurs solides. Bien que ces fonctions ne soient pas bien comprises, FNIII EDA est 
connu comme étant un activateur du Toll-like receptor 4 (TLR4) et semble être impliqué 
dans la progression de diverses maladies de la peau, tandis que d’autres études 
suggèrent également une implication dans la réparation tissulaire. Ainsi, le but de cette 
thèse est de mieux comprendre certaines des fonctions immunologiques et 
régénératives de FNIII EDA et d’appliquer ces résultats dans le développement de 
nouvelles stratégies de vaccination basées sur des protéines endogènes.  
Une tâche importante en vaccinologie est le développement de stratégies 
d’administration présentant l’antigène, ainsi qu’un activateur de TLR, de façon à obtenir 
la réponse immunitaire adaptive désirée. L’utilisation d’activateurs de TLR est associée 
à des contraintes et des soucis parfois sévères liés à la sécurité, causant d’indésirables 
réponses inflammatoires. Ainsi, le développement de vaccins sûrs et efficaces avec de 
faibles effets secondaires est nécessaire et requiert le développement de nouveaux 
adjuvants présentant le bon équilibre entre une forte activation du système 
immunitaire et une faible toxicité pour le patient.  
 10 
 
Ici, en produisant divers fragments de FN contenant FNIII EDA, nous montrons 
que l’activité immunologique de FNIII EDA dépend de son contexte intramoléculaire 
au sein de la chaîne de FN. L’extension N-terminale d’un fragment isolé de FNIII EDA 
par ses domaines adjacents a amplifié son activité activatrice de TLR4, tandis qu’une 
extension C-terminale l’a abrogé. De plus, nous révélons qu’un site de clivage de 
l’elastase 2 est présent entre FNIII EDA et FNIII 12. Comme FNIII EDA est naturellement 
présent dans l’ECM, nous l’avons incorporé dans une matrice de fibrine afin de mimer 
sa situation in vivo et de créer un microenvironnement riche en adjuvant. L’utilisation 
de ces matrices a permis d’induire une réponse fonctionnelle de cellules T CD8+ 
cytotoxiques dans deux modèles de cancer murins. 
En outre, différents activateurs de TLR ont la capacité de synergiser afin d’induire 
une réponse immunitaire plus grande que la somme de leurs effets individuels. Ainsi, 
nous avons démontré que la combinaison de l’activateur de TLR9 CpG avec FNIII EDA 
synergise et induit une réponse immunitaire efficace tout en gardant la dose de CpG a 
un minimum, ce dernier étant potentiellement toxique. Ici la combinaison des deux 
adjuvants a induit une puissante réponse immunitaire suffisante pour ralentir la 
croissance de tumeurs dans un modèle de tumeurs murin ainsi que de casser la 
tolérance immunitaire pour éradiquer le virus de l’hépatite B dans un modèle de souris 
HBV transgéniques. 
Finalement dans la dernière partie de cette thèse nous révélons que FNIII EDA 
est un domaine de liaison de facteurs de croissance, avec une forte affinité pour PDGF-
AA. Nous démontrons également que FNIII EDA et PDGF-AA ont ensemble la capacité 
d’amplifier la prolifération de fibroblastes ainsi que leur différentiation en 
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myofibroblasts. De plus, nous avons exploré les effets d’une matrice de fibrine 
fonctionnalisée avec des variantes de FNIII EDA sur la ré-épithélisation de blessures. 
Mots clés : matrice extracellulaire, fibronectine, FNIII EDA, récepteur de reconnaissance 
de motifs moléculaire, récepteur de type Toll, adjuvant, immunité adaptive, vaccins 
anti-cancereux, HBV, CpG, médecine régénérative, microenvironnement, protéines 
recombinantes, facteurs de croissance, matrice de fibrine  
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1.1 Motivation and aim 
The extracellular matrix (ECM) protein fibronectin (FN) is a remarkably 
multifaceted molecule which despite being extensively studied for over thirty years still 
presents certain functions that remain incompletely elucidated. Some of these 
functions are carried out by the alternatively spliced type III repeat extra domain A 
(FNIII EDA) which presence is crucial during embryogenesis1. Although the type III 
repeat extra domain B (FNIII EDB) is often expressed simultaneously with FNIII EDA 
during cancer-related biological processes and embryogenesis1, its expression within 
tumor is not as consistent as the one observed for FNIII EDA. Perhaps the most 
intriguing function of FNIII EDA is its ability to stimulate the immune system through 
agonization of Toll-like receptor 4 (TLR4) which appears to be involved in the 
progression of different skin diseases2,3 whereas FNIII EDB did not show similar ability. 
Thus, given the unexpected nature of the presence of an endogenous TLR agonist 
within the ECM and the potential for further vaccine applications, this thesis will focus 
on FNIII EDA. 
One of the aims of this thesis is to understand how the surrounding FN type III 
domains of FNIII EDA modulates its immunological activities, addressing the roles of 
its N-terminal and C-terminal extensions. We also sought to understand the 
physiological mechanism allowing the modulation of the immunological activity of 
FNIII EDA by its neighboring domains to take place. We then translated these findings 
to develop new vaccination strategies based on endogenous proteins. Indeed, one 
important task in vaccinology is to develop delivery strategies by which to present 
antigen, along with TLR agonists, so as to induce a desirable adaptive immune 
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response. The use of TLR agonists as adjuvants is associated with sometimes-severe 
constraints and concerns about safety, causing undesirable inflammatory responses. 
FNIII EDA as already been the subject of adjuvant research4–9, inducing modest CD8 T 
cell responses when injected as a soluble adjuvant. As FNIII EDA is naturally present 
within the ECM, we incorporated FNIII EDA bound in matrix to mimic the in vivo 
situation and create an adjuvant-rich-cell-trafficking environment. In addition, matrix-
based vaccines have already proved to be an interesting option for 
immunotherapies10,11. 
Some combinations of TLR-agonists are known to synergize and induce 
responses that are greater than the sum of their individual effect12–14. The strength, and 
most importantly the quality of the response induced by combined TLRs agonists are 
increased15. Thus, the ability of FNIII EDA to synergize with other TLR agonists was also 
explored with the objective to develop potent vaccine formulations able to break 
immune tolerance while keeping the amount of adjuvant to a safe level.  
Finally, we intended to better understand the role of FNIII EDA in tissue repair. 
Interactions between the ECM and growth factors (GF) and cytokines being crucial to 
wound healing16, the interactions between FNIII EDA and numerous signaling 
molecules was also explored. Furthermore, we tried to determine whether the TLR4-
agonization ability of FNIII EDA is involved in the wound re-epithelization process. 
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1.2 Background 
1.2.1 Fibronectin  
Fibronectin (FN) is a multifunctional glycoprotein which is a component of the 
extracellular matrix (ECM) and the blood plasma that is involved in essential biological 
functions such as cell migration, adhesion, growth and differentiation17. In vertebrates, 
FN can be either found as soluble plasma FN (pFN) in the blood or as insoluble cellular 
FN (cFN) in the ECM. The structure of FN is composed of three types of repeating units, 
or domains, and forms dimers of two 220-250kDa monomers17. From the single gene 
that encodes FN, alternative splicing of its mRNA can produce as many as 20 different 
splicing variants in humans18,19. The three types of fibronectin are generally referred to 
as type I, II or III. The repartition of the different FN types and their domains is illustrated 
in Fig. 1 with indication of their most common interaction and integrin binding sites. 
FN is crucial for embryogenesis, as shown by FN gene inactivation leading to 
major embryonic defects and lethality20. It is also essential in wound healing21,22, 
helping restore the ECM and re-epithelization. During the healing process FN 
expression is upregulated, and cFN is one of the main constituent of the granulation 
tissue replacing the provisional matrix21. 
Although the role of FN in embryogenesis and wound healing has already been 
described20–22, its interaction with the immune system is still not fully understood. 
Nevertheless some studies show that such an interaction exists23 as developed in the 
next paragraph. 
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Fig. 1. Fibronectin structure.  Full length FN with its major interaction sites 
displayed  
 
1.2.2 FNIII EDA 
One splicing variant of Fibronectin containing the type III repeat extra domain A 
(FNIII EDA) is normally expressed in the vicinity of developing vessels during 
embryogenesis18,24 and later in particular cases such as after tissue injury25–27, within 
tumors28–30, and at sites of chronic inflammation such as psoriatic lesions3,31,32. FNIII 
EDA has the ability to induce inflammatory cytokines and activate matrix 
metalloproteinases (MMPs) and has been observed to trigger similar reactions to the 
TLR4 ligand lipopolysacchardide (LPS)23. This observation led to the discovery that FNIII 
EDA binds to the TLR4 receptor and activates its signaling pathway leading to the 
activation of NF-κB. However, the physiological consequences of the tight regulation 
of FNIII EDA-containing FN during inflammation and its ability to bind TLR4 are still not 
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fully understood. Furthermore, this activity has been shown to be highly dependent on 
the presence or absence of the neighboring domains of FNIII EDA33. 
Based on the observation that FN III EDA ligates and activates TLR4, one research 
group has explored the use of FNIII EDA as an adjuvant damage-associated molecular 
patterns (DAMP) in subunit vaccines, generating the fusion protein FNIII EDA-antigen8. 
This strategy successfully induced an antigen-specific cytotoxic T-cell response 
although vaccinations have failed to show therapeutic effects in animal models without 
additional adjuvants. However, in spite of a modest effect of FNIII EDA in recombinant 
subunit vaccines, the adjuvancy of FNIII EDA has not been adequate to confer 
protection in viral challenge models in the mouse. As such, it would seem that FNIII 
EDA has the potential to compose a multiple adjuvant vaccine, but insufficiently potent 
to be used on its own. 
 
1.2.3 Functionalized fibrin matrices 
Fibrin, a biopolymer approved by the FDA for use as an adhesive glue, is 
involved in the coagulation cascade. Fibrin matrices form spontaneously in tissue 
repair upon polymerization of fibrinogen, a circulating hexamer glycoprotein clinically 
obtained by cryoprecipitation of human blood plasma. The polymerization process is 
initiated by thrombin, releasing fibrinopeptide A and B from fibrinogen34, resulting in 
fibrinogen monomers. The monomers are then cross-linked by factor XIIIa to form a 
fibrin network35. During its polymerization, fibrin can be functionalized with peptides 
or recombinant proteins modified to contain a transglutaminase substrate sequence 
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derived from α2-plasmin inhibitor (NQEQVSPL) at the N-terminus36. Functionalized 
fibrin matrices have already proved to be an efficient approach towards wound 
healing, serving as an ingenious way to deliver GFs37 in an ECM-like environment. 
However their use in vaccinology remains unexplored. Similarly, FNIII EDA-containing 
FN fragments can be incorporated in fibrin gels in order to mimic its natural in vivo 
context, while creating a microenvironment rich in both adjuvant and antigen. 
 
1.2.4 Dendritic cells and T cells activation 
As an antigen cannot be directly recognized by T cells, it needs to be processed 
and presented by antigen presenting cells (APCs). The immune cells most frequently 
targeted in vaccines include B cells, macrophages, and dendritic cells (DCs), which are 
all effective antigen-presenting cells (APCs). DCs are typically considered the most 
“professional” since they present antigen to their cognate naïve T cell partners and 
instruct them as to how to respond to that antigen. DCs remain in an immature state 
while sampling antigens in their environment to present them to T cells. Upon 
phagocytosis by DCs the antigen will be processed and loaded on major 
histocompatibility complex of class I (MHC-I) or class II (MHC-II) in order to be 
presented. Along with co-stimulatory molecules (CD80, CD86, CD40) and pro-
inflammatory cytokines, presentation on MHC-I will activate naïve CD8+ T cells to 
cytotoxic T lymphocytes (Fig. 2) while presentation on MHC-II will activate naïve CD4+ 
T helper cells (Fig. 2), which can be characterized mainly either by a T helper 1 (Th1) or 
2 (Th2) polarization. Th1 cells promoting a CD8+ T cell response and Th2 cells 
promoting a humoral response through help to B cells. 
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Fig. 2. Schematic overview of antigen presentation. Ag presentation by DCs via 
MHC class I and class II molecules accompanied by a second signal leads to activation, 
proliferation and differentiation of respectively Ag-specific CD4+ and CD8+ T cells. Th1 
cells provide help to CD8+ T cells, while Th2 cells provide help to B cells. Figure and 
legend adapted from a review by De Temmermann M.-L. et al.38 
 
In addition to their ability to present antigens, DCs can recognize pathogen 
associated molecular patterns (PAMPs) from foreign agents such as bacteria and virus 
through pattern recognition receptors (PRR), a type of receptors which include TLRs. In 
addition, many endogenous molecules can also trigger DCs activation; such molecules 
known as DAMPs are typically associated with tissue damage or distress. 
Activating ligands have been identified for most of the 13 human TLRs, with most 
of these ligands stemming from bacterial or viral origins. Common pathogenic ligands 
include LPS for TLR4, flagellin for TLR5 and CpG DNA for TLR9; however, endogenous 
ligands have also been identified. Signaling downstream of TLRs will mature the DCs, 
leading to immunity towards the antigen, whereas the absence of TLR signaling might 
keep the DCs from maturing after taking up the antigen and lead to the opposite effect 
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known as tolerance39. The response that a DC elicits depends on many factors, 
including the state of maturation of the DC, how the antigen was taken up and 
processed by the cell, and even the tissue in which the DC was activated. Importantly, 
the cytokine environment in which both DC activation and DC-T cell communication 
occurs can control the response and should be considered when choosing tissue 
targets. These cytokines can be secreted by DCs upon activation or inactivation, by the 
activated T cells themselves, by recruited neutrophils and macrophages to the 
inflammatory site, and finally, by stromal cells that can become activated during 
inflammation. Because the cytokine profile present during contact with the DC can 
determine T cell fate, engineering approaches that manipulate or utilize the cytokine 
environment are important design considerations. 
 
1.2.5 Cancer immunotherapies 
Existing cancer therapies include surgery, radio therapy, chemotherapy and more 
recently immunotherapy. Immunotherapies present the advantage over older types of 
treatments to be more efficient as they are designed to specifically target cancerous 
cells, thus limiting the damage to non-tumoral cells. Although various cancer 
immunotherapy strategies exist, cellular immunotherapies, also called cancer vaccines, 
will be the one of interest here. 
Multiple characteristics need to be met for a cancer vaccine to be effective. 
Cancer vaccines need to be targeted to an antigen specific to the tumor in order to 
avoid harming healthy cells. Hence antigen identification still presents a challenge and 
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for these reasons the research presented in this thesis will use tumor models with 
known antigens. As tumor cells derive from endogenous cells their antigens are hardly 
targeted by the immune system and a proper danger signal need to be provided to 
mount an immune response against them. However many challenges are present when 
trying to mount an effective anti-tumoral immune response. Not only tumor antigens 
are not recognized as foreign by the immune system but they are also both centrally 
and peripherally tolerized40, thus requiring an immune response sufficiently strong to 
break immune tolerance to self-neo-antigen. Furthermore tumor cells are able to 
create an immunosuppressive microenvironment, attracting high levels of Myeloid-
derived suppressor cells (MDSC) and/or regulatory T-cells (Tregs)41, which the T cells 
need to resist42,43. Thus formulations with the ability to modulate tumor immune 
suppression by controlling the population of MDSCs or Tregs are more suited to make 
effective therapeutic cancer vaccines44.  
Selection of the appropriate adjuvant, molecules that activate APCs to stimulate 
immune responses, is required. At the present time aluminum-based salts and a 
squalene-oil-water emulsion are approved for clinical use although they present 
limitations. The effective vaccine also should trigger the innate immune system to 
stimulate the production of Th1-polarizing cytokine to promote the efficiency of T cell 
priming45. It should also should seek to provide long-term memory to prevent tumor 
recurrence. 
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1.3 Accomplishments 
In this work we explore and further characterize both the immunological and 
regenerative functions of FNIII EDA. In chapter 2, we explore the importance of the 
molecular context of FNIII EDA in its ability to activate TLR4. Here we reveal that the 
TLR4 agonizing potential of FNIII EDA is cryptic, becoming exposed by cleavage 
between FNIII EDA and FNIII 12 by elastase 2. Upon proteolysis, TLR4 agonization was 
increased up to 5 fold. We demonstrate using two tumor models that induction of CTL 
responses to a xeno- and an auto-antigen by FNIII EDA activity is enhanced when the 
domain is bound to an ECM analog. Thus we show that delivering ECM-bound FNIII 
EDA fragments in combination with antigens could be an attractive option for anti-
tumoral immunotherapies. 
In chapter 3, using a tumor model and a chronic hepatitis B transgenic mouse 
model expressing an HBV transgene we show that the TLR9 agonist unmethylated CpG 
oligodeoxynucleotide and FNIII 11-EDA have the ability to synergize to break T cell 
tolerance and induce an enhanced antigen specific response. It is important that these 
improved effects were obtained while lowering the total dose of foreign agent (CpG), 
opening the door to the development of potent immunotherapies with fewer side 
effects and improved safety. 
Finally, in chapter 4 we show that FNIII EDA is yet another GF binding domain of 
FN, with an especially strong affinity for PDGF-AA. Our results here suggest that FNIII 
11-EDA and PDGF-AA have together the ability to enhance fibroblasts proliferation and 
differentiation into myofibroblasts although additional experiments are still required 
to further investigate a potential synergy between these proteins. We show that fibrin 
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matrices functionalized with variants of FNIII 11-EDA surprisingly delay wound closure, 
however here again more experiment will be required to precisely characterize how 
FNIII EDA affects tissue repair.  
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2.1 Abstract 
Fibronectin (FN) is an extracellular matrix (ECM) protein including numerous 
fibronectin type III (FNIII) repeats with different functions. The alternatively spliced FN 
variant containing the extra domain A (FNIII EDA), located between FNIII 11 and FNIII 
12, is expressed in sites of injury, chronic inflammation, and solid tumors. Although its 
function is not well understood, FNIII EDA is known to agonize Toll-like receptor 4 
(TLR4). Here, by producing various FN fragments containing FNIII EDA, we found that 
FNIII EDA’s immunological activity depends upon its local intramolecular context within 
the FN chain. N-terminal extension of the isolated FNIII EDA with its neighboring FNIII 
repeats (FNIII 9-10-11) enhanced its activity in agonizing TLR4, while C-terminal 
extension with the native FNIII 12-13-14 heparin-binding domain abrogated it. In 
addition, we reveal that an elastase 2 cleavage site is present between FNIII EDA and 
FNIII 12. Activity of the C-terminally extended FNIII EDA could be restored after 
cleavage of the FNIII 12-13-14 domain by elastase 2. FN being naturally bound to the 
ECM, we immobilized FNIII EDA-containing FN fragments within a fibrin matrix model 
along with antigenic peptides. Such matrices were shown to stimulate cytotoxic CD8+ 
T cell responses in two murine cancer models. 
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2.2 Introduction 
Fibronectin (FN) is a ubiquitous multidomain extracellular matrix (ECM) 
component and is critically important in numerous ECM-dependent processes such as 
cell adhesion, migration, growth, and differentiation1. Notably, certain functions of FN 
depend on the presence of the alternatively spliced type III repeats extra domains A 
(FNIII EDA) and B (FNIII EDB). These extra domains are expressed in the vicinity of 
developing vessels during embryogenesis2,3 and later in particular cases such as after 
tissue injury4–6, within tumors7–9, and at sites of chronic inflammation such as psoriatic 
lesions10–12. Although expression of FNIII EDA and FNIII EDB is crucial for embryonic 
development13, their postnatal functions remain incompletely elucidated. 
One of the most interesting functions of FNIII EDA is its ability to act as an 
endogenous ligand for the pattern recognition receptor Toll-like receptor 4 (TLR4)14 
and activate its signaling pathway, which leads to the activation of NF-κB. Importantly, 
this TLR4-agonizing activity has been shown to contribute to disease progression, 
specifically in driving fibrosis in scleroderma15 and stimulating the inflammatory 
cascade in psoriatic lesions10. 
Here, we sought to explore the importance of the local molecular context of FNIII 
EDA in its immunological activities, as the domain resides in the vicinity of other active 
FNIII repeats in the natural sequence FNIII 9-10-11-EDA-12-13-14 (Fig. 1a). FNIII 10 
contains the well-studied RGD sequence that binds integrins such as αvβ3
16 and FNIII 9 
contains the synergy site PHSRN that is critical for α5β1 integrin activation
17. FNIII 11 
has been shown to bind anastellin18, a small FN type I fragment, increasing its 
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thermolytic digestion. The FNIII 12-13-14 domain is one of the major heparin-binding 
sites of FN19 and has been shown to promiscuously bind growth factors20,21. In some of 
FN’s biological activities, this molecular context has been shown to be important; for 
example, the proximal location of the integrin-binding domain and the growth factor 
binding domain has been shown to lead to synergistic signaling between the ligated 
integrin and the ligated growth factor receptor, potentiating growth factor signaling21–
23. Based on these recent findings, we were motivated to investigate the potential 
importance of the molecular context of FNIII EDA’s placement within the FN chain upon 
its activity in inducing immune responses. 
Moreover, FNIII EDA is known to induce the expression of inflammatory cytokines 
and matrix metalloproteinases (MMPs)24, and these activities have been shown to be 
dependent on the presence of the neighboring domains FNIII11 and FNIII1224. For such 
exposure to occur in vivo, it would require FN to be cleaved by a protease, but only the 
bacterial protease thermolysin from Bacillus thermoproteolyticus has been shown to 
cleave FN close to the C-terminus of FNIII EDA25. Because no mammalian protease had 
been shown to carry out the same function, we were thus also motivated to search for 
mammalian proteases that might modulate the activity of FNIII EDA by inducing such 
cleavage. 
Finally, because FNIII EDA can induce cellular immune responses including 
activation of CD8+ T cell responses26–31, the domain has also been explored as a cancer 
vaccine adjuvant in mouse models28,30,31. However, FNIII EDA showed potency mostly 
in combination with other TLR agonists28,31. Here, because FNIII EDA is naturally 
displayed bound to the ECM, we hypothesized that its relatively weak adjuvancy could 
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be related to the fact that the domain was delivered as a soluble protein. Therefore, we 
also explored whether FNIII EDA variants could have better adjuvant potency when 
bound to the ECM. 
 
2.3 Results 
2.3.1 Production of FN fragments 
To investigate the importance of the biomolecular context of FNIII EDA’s activity 
as a TLR4 agonist, we expressed various FN fragments containing FNIII EDA (Fig. 1a). 
As the simplest construct, FNIII EDA was produced as a single FNIII repeat. Extending 
N-terminally, FNIII 11 was incorporated to produce FNIII 11-EDA. To further explore N-
terminal extensions, FNIII 9-10-EDA and FNIII 9-10-11-EDA were expressed, thus 
comprising the cell-binding domain with the synergy site1. To explore C-terminal 
extensions, FNIII 9-10-EDA-12-13-14 and FNIII 9-10-11-EDA-12-13-14 were expressed, 
thus comprising the FNIII 12-13-14 domain, which binds heparin1 and growth factors20. 
All FN fragments were successfully produced, and endotoxin levels were verified as 
being under 0.2 EU/µg using a limulus amebocyte lysate assay. Purity of the FN 
fragments is shown by SDS-PAGE in Fig. S1a. 
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2.3.2 The immunostimulatory activity of FNIII EDA can be 
modulated by addition or deletion of neighboring domains 
To explore the dependence of TLR4 agonization upon the presence of various 
neighboring domains in the FN protein chain, we characterized TLR agonization using 
THP1-Blue cells (derived from the human monocytic THP1 cell line and modified to 
contain a reporter of agonization of several TLRs) and HEK-Blue TLR4 cells (derived 
from the human embryonic kidney 293 cell line and modified to contain a reporter of 
agonization of TLR4) as well as cytokine expression in dendritic cells (DCs). As expected, 
FNIII EDA agonized TLR4 in THP1-Blue cells in a dose-dependent manner (Fig. 1b). 
Interestingly, addition of FNIII 11 at the N-terminus, i.e. FNIII 11-EDA, agonized TLR4 
up to 4-fold more potently (P<0.001) in THP1-Blue cells and up to 5-fold more potently 
(P<0.001) in HEK-Blue TLR4 cells, compared to FNIII EDA (Fig. 1b, c). To explore if this 
gain of activity derived from intrinsic activity within FNIII 11 or from an effect of N-
terminal extension, which could for example influence the stability of the FNIII EDA 
domain, we produced the alternative construct FNIII 9-10-EDA, i.e. containing a 
neighboring N-terminal extension with FN’s cell-binding domain and synergy site yet 
not the N-terminal FNIII 11 domain. Surprisingly, FNIII 9-10-EDA agonized TLR4 to the 
same extent as FNIII 11-EDA in both cell lines. Moreover, the complete N-terminal 
construct, FNIII 9-10-11-EDA, showed statistically equivalent behavior (Fig. 1b, c). We 
further explored the impact of neighboring FNIII repeats by extending FNIII EDA to the 
C-terminus with the native structure FNIII 9-10-11-EDA-12-13-14, as well as FNIII 9-10-
EDA-12-13-14. Unexpectedly, in both THP1-Blue and HEK-Blue TLR4 cells, C-terminal 
extension with the FNIII 12-13-14 domain abrogated TLR4 agonization (Fig.1b, c). We 
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then tested the ability of the different FNIII EDA-containing constructs to stimulate the 
production of inflammatory cytokines in DCs, which are key monitors of innate immune 
signals such as TLR4 agonists. DC expression of TNF-α and IL-12p70 closely paralleled 
the TLR4 agonization that was observed in THP1-Blue and HEK-Blue TLR4 cells. The N-
terminal extension of FNIII EDA strongly enhanced cytokine response, while C-terminal 
extension with FNIII 12-13-14 strongly decreased it (Fig.1d, e). 
 
 
Fig. 1. TLR4 activation by FNIII EDA is modulated by the context of its 
neighboring FNIII domains. (a) FNIII EDA-containing FN fragments produced and of 
full length FN with some of its interaction sites displayed. (b) Activation of NF-κB in 
THP1-Blue cells as an indication of TLR agonization in response to various FNIII EDA-
containing FN fragments, compared to LPS. The presence of a domain N-terminal to 
the FNIII EDA domain enhances activation, and the neighboring C-terminal domain 
abrogates activation. In the absence of the FNIII 12-13-14 domain, activation is 
comparable to that achieved by LPS. (c) Activation of NF-κB in HEK-Blue TLR4 cells as 
a cellular bioassay of TLR4 agonization. The presence of a domain N-terminal to the 
FNIII EDA domain enhances TLR4 agonization, and the neighboring C-terminal domain 
abrogates TLR4 agonization. In the absence of the FNIII 12-13-14 domain, TLR4 
agonization is strong. (d, e) Production of TNF-α (d) or IL-12p70 (e) from murine bone 
marrow-derived DCs upon stimulation with various FNIII EDA-containing FN 
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fragments. In DCs, the same pattern of activation was observed as with the previous 
cell lines: the presence of a domain N-terminal to the FNIII EDA domain enhances 
activation, and the neighboring FNIII 12-13-14 domain abrogates activation. (f) 
Western blots of the digestion product of FNIII 9-10-EDA-12-13-14 by elastase 2 and 
undigested control, blotted against the FNIII EDA domain (N-terminal to a predicted 
elastase 2 cleavage site) and a 6xHis tag (C-terminal). Cleavage was observed to yield 
two fragments of similar molecular weight, consistent with the presence of elastase 2 
cleavage site at position 87 of the 94 amino acid-long FNIII EDA domain. (g) Activation 
of HEK-Blue TLR4 cells with the digested and undigested FNIII 9-10-EDA-12-13-14. 
Digestion of FNIII 9-10-EDA-12-13-14 with elastase 2 recovers activation, consistent 
with elastase 2-dependent cryptic agonization of TLR4. Cellular experiments in c, d, e 
and f were done in the presence of 10 µg/ml polymixin B, to avoid any influence of 
potentially contaminating LPS. In c, d, e and f, bars and curves represent mean ± SEM 
of triplicate cultures from two independent experiments. **P < 0.01; ***P < 0.001. 
 
2.3.3 The immunostimulatory activity of FNIII EDA is cryptic and 
dependent upon elastase 2 cleavage 
We sought to understand the biological significance of the profound diminution 
of FNIII EDA activity through C-terminal extension with the FNIII 12-13-14 domain, 
hypothesizing that the FNIII EDA repeat is cryptic in its TLR4 agonizing activity. Using 
bioinformatics analytical tools32, we suspected the presence of an elastase 2 (a serine 
protease, also referred to as neutrophil elastase) substrate between FNIII EDA and FNIII 
12, after ile87 in the 94 amino acid-long FNIII EDA domain. We verified the presence of 
such a cleavage site by incubating FNIII 9-10-EDA-12-14 with elastase 2. The digestion 
products were analyzed using Western blotting, detecting FNIII EDA or the 6xHis tag 
that is located at the C-terminus of the FN fragment. Therefore, the expected digestion 
products of the 67 kDa FNIII 9-10-EDA-12-14 protein are a 33 kDa FNIII EDA-positive 
fragment and a 34 kDa 6xHis tag-positive fragment. Western blotting confirmed the 
presence of the cleavage site, since both digestion products were detected (Fig.1f). 
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To assess if the biological activity of FNIII 9-10-EDA-12-14 could be recovered 
after digestion by elastase 2, we characterized TLR4 agonization in the HEK-Blue TLR4 
cells. Proteolytic enhancement of TLR4 agonization was observed (Fig. 1g), consistent 
with activity obtained with the recombinant fragments lacking FNIII12-14 although not 
as high. The elastase 2 enzyme itself did not activate TLR4 in this assay (Fig. 1g). Other 
proteases tested (MMP-2, MMP-3, MMP-9, thrombin and plasmin) did not show 
cleavage of the protein as indicated by SDS-PAGE analysis (Fig. S1b). 
 
 
Fig. 2. Fibrin matrices functionalized with FNIII 9-10 + FNIII 11-EDA stimulate an 
antigen-specific CD8+ T cell response. (a) Immunization schedule. C57BL/6J mice 
were immunized with 50 µg OVA and 20 µg LPS on day 0. The ability of FNIII EDA-
containing fibrin-binding FN fragments to boost a CD8+ T cell response was tested on 
day 14 by implanting s.c. fibrin matrices functionalized with 5 nmol of TG-OVA250–264 
(comprising the MHC-I binding immunodominant peptide of ovalbumin, OVA257–264) + 
5 nmol of FNIII 11-EDA or FNIII 9-10-EDA (each with an N-terminal TG domain); 
alternatively mice were injected i.d. with 5 nmol of soluble OVA257-264 + 50 µg of LPS or 
with PBS only. On day 19, mice were sacrificed and the spleen was harvested. (b) Fibrin 
gels functionalized with fibrin-binding FNIII 9-10 + FNIII 11-EDA (each with an N-
terminal TG domain) + TG-OVA250–264 induced levels of OVA257-264-MHC-I-specific CD8
+ 
T cells in the spleen comparable to that induced by i.d. injections of LPS + OVA257-264. 
(c, d) IFN-γ production from splenocytes restimulated for 6 h ex vivo with OVA257-264 
were evaluated by flow cytometry. The proportion of IFN-γ producing CD8+ T cell was 
similar among the different groups. However, the production of IFN-γ by CD8+ T cells 
was greater, as shown by the mean fluorescence intensity (MFI) of IFN-γ intracellular 
staining, in mice that were boosted with fibrin matrices functionalized with FNIII 9-10 
+ FNIII 11-EDA (each with an N-terminal TG domain) + TG-OVA250-264 or with LPS and 
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OVA257-264; the group boosted with FNIII 11-EDA yielded statistically similar responses 
as the group boosted with LPS. Box plots represent median ± 95% confidence interval 
(n = 5). *P < 0.05; ns, not significant. 
 
2.3.4 Fibrin matrices functionalized with FNIII 9-10 + FNIII 11-EDA 
mediate CD8+ T cell expansion and effector phenotype 
Since FNIII 11-EDA showed potent TLR4 activation in vitro, we evaluated its 
immunological activity in vivo. We selected a model based on the xenoantigen 
ovalbumin (OVA), in which vaccine-induced weak CD8+ T cell responses could 
potentially be further boosted (Fig. 2a). To evaluate boosting the CD8+ T cell responses, 
we co-delivered FNIII 11-EDA and the H2kb MHC I immunodominant peptide OVA257–
264
33. Because FNIII EDA is naturally present within FN in the ECM, we decided to 
incorporate the FN fragments bound in matrix to mimic the in vivo situation. Moreover, 
this strategy allows creating an adjuvant-rich microenvironment, which has proved to 
be successful for cancer vaccination in other studies34. Here, as a matrix model, we used 
a fibrin hydrogel resembling a fibrin clot, with a volume of 150 µL and a concentration 
of 8 mg/mL of fibrinogen. To be incorporated in the matrix, the FN fragments were 
designed to contain a transglutaminase substrate sequence derived from α2-plasmin 
inhibitor (NQEQVSPL, denoted herein TG) at the N-terminus. Therefore, the FN 
fragments could be covalently incorporated in the matrix through the transglutaminase 
activity of factor XIIIa, which naturally crosslinks fibrin35. In addition, the OVA257–264 
peptide was designed to be incorporated in fibrin. The TG sequence was fused to a 
longer sequence of OVA, namely OVA250–264, so as to comprise the protease substrate 
site SGLEQLE within the OVA chain that allows processing by APC antigen proteolysis 
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machinery and liberation of the OVA257–264 epitope from TG-OVA250-264 for cross-
presentation on MHC I36 . Furthermore, because cell migration within fibrin is enhanced 
by integrin binding, we incorporated the major integrin-binding domain of FN, FNIII 9-
1037. Two fibrin matrix compositions were tested: fibrin functionalized with FNIII 9-10 
plus FNIII 11-EDA and fibrin functionalized with FNIII 9-10-EDA. 
First, we gave an intradermal (i.d.) vaccine prime dose of soluble OVA adjuvanted 
with lipopolysaccaride (LPS), which resulted in strong CD4+ but modest CD8+ T cell 
responses, as indicated by OVA257-264:H2k
b p:MHC I pentamer binding (Fig. 2b). FNIII 
EDA being rarely the initiator of the inflammatory response in vivo, priming with this 
formulation to better study FNIII EDA in its ability to sustain a pre-established 
inflammatory response. Boosting with the soluble MHC I epitope OVA257–264 + LPS 
increased the frequency of antigen-specific CD8+ T cells (P<0.05). Boosting was also 
achieved by implanting fibrin matrices functionalized with FNIII 9-10 + FNIII 11-EDA + 
TG-OVA250–264 (P<0.05) and with FNIII 9-10-EDA + TG-OVA250–264 (P<0.05), although the 
boosting was marginally improved with the former (Fig. 2b). As an indication of the 
effector phenotype of these cells, we performed ex vivo restimulation of splenocytes 
with OVA257-264: although the frequency of IFN-γ-expressing CD8
+ T cells was not 
enhanced by the FNIII EDA-containing proteins (Fig. 2c), the intensity of IFN-γ 
expression was enhanced by treatment with fibrin functionalized with FNIII 9-10 + FNIII 
11-EDA (P<0.05) (Fig. 2d). 
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Fig. 3. Single implantation of fibrin matrices functionalized with FNIII 9-10 + FNIII 
11-EDA in E.G7-OVA tumor bearing mice reduces tumor growth rate. C57BL/6J 
mice were injected s.c. with 106 E.G7-OVA cells on the back. When tumors reached 50 
± 5 mm3, the ability of fibrin-binding FNIII EDA-containing FN fragments to induce a 
functional CD8+ T cell response was tested by treating mice with fibrin matrices 
functionalized with various matrix formulations implanted s.c. or with soluble 
formulations injected i.d. Animals were sacrificed either when the tumor reached 1000 
mm3 or for humane reasons. (a, b) Tumor growth was significantly delayed in animals 
vaccinated using a fibrin matrix functionalized with FNIII 11-EDA ± FNIII 9-10 (each 
with an N-terminal TG domain) + TG-OVA250-264 both in terms of tumor volume (a) and 
animal survival (b). TG-OVA250-264-free matrices also proved slightly effective in delaying 
tumor growth (a) and extending animal survival (b). Growth curves were stopped when 
the second animal of the corresponding group died, the value corresponding to the 
first animal which died was kept as a constant until the curve was stopped. Growth 
curves represent mean ± SEM; Kaplan-Meier survival-curves (n = 4-9) from two 
independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. 
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2.3.5 Fibrin matrices functionalized with FNIII 11-EDA ± FNIII 9-10 
mediate functional cytotoxic T lymphocyte responses in the 
E.G7-OVA tumor model 
To explore the extent to which FNIII 11-EDA-generated CD8+ T cells were capable 
of cell killing, i.e. function as cytotoxic T lymphocytes (CTLs), we employed a thymoma 
tumor model in which the cells express the xenoantigen OVA (E.G7-OVA). Tumor cells 
were injected subcutaneously (s.c.) in the back, and resulting tumors were allowed to 
reach a volume of 50 mm3. At that point, a fibrin matrix containing the FN fragments 
of interest and TG-OVA250–264 was implanted at a distant site at the level of the shoulder 
girdle close to the brachial lymph nodes or soluble OVA257-264 controls were injected 
i.d. in the four footpads, and delays in tumor growth were measured. Soluble controls 
were injected i.d. in the four footpads. 
When the fibrin matrix was implanted only once, strong delays in tumor growth 
were observed with treatments comprising FNIII 11-EDA, especially in conjunction with 
FNIII 9-10 (Fig. 3a). Omission of FNIII 11-EDA from the fibrin matrix resulted in no delay 
of tumor growth. Although the TG-OVA250–264 peptide-free FNIII-EDA-containing matrix 
slightly reduced the tumor growth, the absence of antigen significantly reduced the 
response, demonstrating that the response is not mainly based on a general 
upregulation of immunity but is rather specific to the antigen co-incorporated in the 
fibrin matrix. Moreover, FNIII 9-10 + FNIII 11-EDA was not as effective when 
administered not bound to fibrin matrix, demonstrating functionality in the matrix-
immobilized form. The Kaplan-Meier survival curves shown in Fig. 3b illustrate the 
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benefits of co-delivery of FNIII 9-10 and FNIII 11-EDA with the tumor cell-specific 
peptide epitope. Although all tumors eventually reached 1000 mm3, the substantial 
delay in approaching this volume induced by a fibrin matrix with FNIII 11-EDA, 
especially in conjunction with FNIII 9-10, clearly indicates induction of functional CTL 
responses. 
In the experiments described above, a single administration of a functionalized 
fibrin matrix was performed and the fibrin was slowly resorbed, whereas physiologically 
the FNIII EDA-containing FN proteolytic fragments would be present chronically. Thus, 
to further explore the ability of its chronic presence to induce CTL activity, we 
administered the functional fibrin matrices weekly after the tumors reached 50 mm3. In 
this model also, tumor growth was significantly delayed in animals treated with fibrin 
matrices functionalized with FNIII 11-EDA ± FNIII 9-10 + TG-OVA250–264 both in terms 
of tumor volume (Fig. 4a) and survival (Fig. 4b). Furthermore, none of the mice treated 
with PBS or with fibrin matrices lacking either FNIII 11-EDA or TG-OVA250–264 survived 
more than 21 days post treatment, whereas half of the mice treated with fibrin matrices 
functionalized with FNIII 11-EDA + TG-OVA250–264 ± FNIII 9-10 survived longer than 21 
days and 20% even showed complete regression of the tumor, as shown in survival 
curves (Fig. 4b) and the individual growth curves (Fig. 4c). The efficacy of multiple 
injections of the soluble formulation was not assessed here as that approach already 
proved to be significantly less effective than functionalized fibrin matrix forms with a 
single administration. In this model of chronic exposure, co-treatment with FNIII 9-10 
and FNIII 11-EDA yielded stronger CTL responses than mono-treatment with FNIII 11-
EDA, both with the TG-OVA250–264 peptide antigen comprising the OVA257–264 epitope. 
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Fig. 4. Multiple implantations of fibrin matrices functionalized with FNIII 11-EDA 
± FNIII 9-10 reduces E.G7-OVA tumor growth rate and in cases mediates 
regression. C57BL/6J mice were injected s.c. with 106 E.G7-OVA cells on the back. 
When tumors reached 50 ± 5 mm3, mice were treated weekly (day 0 and dashed lines) 
for three weeks with fibrin matrices functionalized with various formulations implanted 
s.c. Mice were sacrificed when the tumor reached 1000 mm3 or for humane reasons. 
Tumor growth was significantly delayed in animals treated using a fibrin matrix 
functionalized with FNIII 11-EDA ± FNIII 9-10 (each with an N-terminal TG domain) + 
TG-OVA257-264 both in terms of tumor volume (a) and animal survival (b). Individual 
growth curves (c) show regression in some of the animals treated with fibrin gels 
functionalized with TG-OVA250-264 and FNIII 11-EDA with or without FNIII 9-10 (each 
with an N-terminal TG domain). Growth curves were stopped when the second animal 
of the corresponding group died, the value corresponding to the first animal which 
died was kept as a constant until the curve was stopped. Growth curves represent mean 
± SEM; Kaplan-Meier survival-curves (n = 6-12) from two independent experiments. *P 
< 0.05;***P < 0.001. 
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2.3.6 Fibrin matrices functionalized with FNIII 9-10 + FNIII 11-EDA 
mediate functional cytotoxic T lymphocyte responses in the 
B16-F10 tumor model with an endogenous antigen 
In the experiments with E.G7-OVA cells, the surrogate tumor antigen OVA is a 
xenoantigen, not centrally tolerized in the mouse. To explore the activity of the FNIII 
11-EDA domain to induce immunological responses versus a centrally tolerized 
antigen, we used the B16-F10 melanoma model. Fibrin matrices were functionalized 
with FNIII EDA-containing FN fragments and with the MHC I immunodominant epitope 
from tyrosinase-related protein-2 (TRP-2), namely TRP-2180-188
38. As with the OVA-
derived epitope, we designed the TRP-2-derived epitope to contain a longer peptide 
sequence from TRP-2 for proteolytic processing of the antigen and an N-terminal TG 
sequence for immobilization in fibrin, namely TG-TRP-2173-188. Mice were treated 
starting from the third day after tumor inoculation, when the tumors were palpable, 
and were further treated weekly for three weeks. Consistent with the results in the E.G7-
OVA model, tumor growth was significantly delayed in animals treated with the fibrin 
matrix functionalized with FNIII 11-EDA + FNIII 9-10 + TG-TRP-2173-188, as shown by the 
individual (Fig. 5a) and aggregate (Fig. 5b) growth curves, as well as the Kaplan-Meier 
survival curves (Fig. 5c). As in the experiments with the E.G7-OVA cells, the combination 
of the antigen with either FNIII 11-EDA or FNIII 11-EDA + FNIII 9-10 yielded similar 
results; only the latter, which proved slightly more effective at reducing the initial tumor 
volume, was retained for testing against the aggressive B16-F10 model. 
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The B16-F10 melanoma model is known as an immune suppressive model, owing 
in part to the infiltration of monocytic myeloid-derived suppressor cells (MO-MDSCs) 
in the tumor as well as their proliferation in the spleen39,40. Therefore, we examined 
MO-MDSC numbers in the spleens of the B16-F10-bearing mice. Mice receiving the 
fibrin matrices containing TG-TRP-2173-188 but no FNIII fragments showed the same 
number of splenic MO-MDSCs compared to untreated mice or mice treated with fibrin 
matrices functionalized with FNIII 11-EDA + FNIII 9-10 without TG-TRP-2173-188. 
However, mice treated with fibrin matrices functionalized with FNIII 11-EDA + FNIII 9-
10 + TG-TRP-2173-188 showed a substantial reduction in the number of splenic MO-
MDSCs, demonstrating the ability of the FNIII 11-EDA domain to induce local (delay of 
tumor growth) and systemic (reduction in splenic MO-MDSC numbers) immune 
responses to an endogenous antigen, here the melanocyte-specific antigen TRP-2. 
 
Fig. 5. Multiple implantations of fibrin matrices functionalized with FNIII 9-10 + 
FNIII 11-EDA reduces B16-F10 melanoma tumor growth rate and modulates anti-
tumor immune suppression. C57BL/6J mice were injected s.c. with 2.5 x 105 B16-F10 
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cells on the back on day 0. On day 3, mice were treated weekly (dashed lines) for three 
weeks with fibrin gels functionalized with various formulations implanted s.c. Animal 
were sacrificed either when the tumor reached 200 mm3 or for humane reasons. 
Individual growth curves (a) and survival curves (b) show that tumor growth was 
significantly delayed in animals treated with fibrin matrices functionalized with FNIII 
11-EDA + FNIII 9-10 (each with an N-terminal TG domain) + TG-TRP-2173-188, 
comprising the MHC-I immunodominant peptide epitope from the melanocyte-
specific protein TRP-2 (TRP-2180-188). (c) The percentage of monocytic myeloid-derived 
suppressor cells (MO-MDSC, flow-cytometry gated as being CD11b+CD11c-MHC-II-
Ly6ChiLy6G-) in the spleen was significantly reduced in the mice treated with the fibrin 
gel containing and FNIII 9-10 + FNIII 11-EDA (each with an N-terminal TG domain) + 
TG-TRP-2173-188 compared to the naïve control. Graphs show Kaplan-Meier survival-
curves (n = 6-12) from two independent experiments. Box plots represent median ± 
95% confidence interval (n = 3-5). *P < 0.05; **P < 0.01. 
 
2.4 Discussion 
Although roles of FN in processes such as embryogenesis and wound healing 
have been described41,42, FN’s interaction with the immune system is not well 
understood. The FNIII EDA domain, present in a splice variant of FN, which is found in 
sites of transient inflammation as in tissue damage4–6 and of chronic inflammation such 
as psoriatic lesions10–12 and scleroderma lesions15, has been shown to agonize TLR414. 
In the case of scleroderma, for example, agonization of TLR4 was shown to drive a cycle 
of fibrosis, leading to further FNIII EDA-containing FN expression, increasing TLR4 
agonization and promoting continued fibrosis15; as such, TLR4 agonization via FNIII 
EDA is central to the pathophysiology of the disease. Moreover, because of its ability 
to activate TLR4, FNIII EDA has been explored in cancer vaccinology, utilizing FNIII EDA-
antigen fusion proteins as DC-targeting adjuvants to induce anti-tumor CTLs28,30,31. In 
this work, at least part of the effect of the FNIII EDA domain has been attributed to 
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targeting the antigen for DC uptake through binding to TLR428,30. Nevertheless, FNIII 
EDA showed anti-tumor potency only in combination with other TLR ligands. 
In our study, we first sought to explore the dependence of FNIII EDA’s 
agonization of TLR4 on its intramolecular context, addressing roles played by the N-
terminally neighboring FNIII 11 domain and FNIII 9-10 domain, which binds cell-surface 
integrins α5β1 and αvβ3
1,16,17,43, and by the C-terminally neighboring domain FNIII 12-
13-14, which binds heparin and heparan sulfate19 and growth factors21. Moreover, we 
hypothesized that the agonization of TLR4 by FNIII EDA could be cryptic, because some 
of the physiological mechanisms involving FN have been shown to be carried out by 
cryptic sites44–47 requiring conformational modification or proteolytic cleavage to exert 
their functions, including stimulation of MMP expression by FNIII EDA24. Thus, we were 
also motivated to search for proteases that might enhance FNIII EDA activity. 
We expressed a family of FN fragments (Fig. 1a) comprising the FNIII EDA repeat 
with various N-terminal and C-terminal extensions, so as to include FNIII 9-10, FNIII 11, 
and FNIII 12-13-14. Then, we characterized the ability of these recombinant FN 
fragments to agonize TLR4, activate DCs, stimulate CD8+ T cell expansion, and induce 
functional CTLs, where functionality was judged by cytotoxicity in a tumor vaccine 
model. Our in vitro results show that extension of the FNIII EDA domain to the N-
terminus enhances its ability to agonize TLR4 (Fig. 1b, c) and induce inflammatory 
cytokine expression from DCs (Fig. 1d, e). This phenomenon was not sensitive to the 
details of the FNIII domain to the N-terminus, as extensions with FNIII 11, FNIII 9-10, 
and FNIII 9-10-11 yielded equivalent results (Fig. 1b, e). Thus, we conclude that co-
binding of integrins α5β1 and αvβ3 is likely not involved in the effect. Rather, the 
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observed 4-5 fold enhancement of TLR4-agonization activity may be due to structural 
stabilization of the FNIII EDA repeat, which, like other FNIII domains, is not stabilized 
by disulfide bonding. It is noteworthy that agonization of TLR4 by N-terminally 
extended FNIII EDA is very potent, comparable to that achieved by the prototypical 
microbial TLR4 agonist LPS (Fig.1b), yet without the cytotoxicity that is accompanied 
by high doses of LPS, which leads to lower NF-κB signaling48 (Fig. 1b). Furthermore, the 
protein construct tested here were stable at concentration, showing no aggregation. 
The possibility that our fragments could be contaminated with LPS was excluded 
by conducting these experiments in the presence of polymyxin B, which binds and 
inactivates LPS49,50; moreover, the expression and purification protocol for FNIII EDA 
(observed to be a poor agonist) and FNIII 11-EDA, FNIII 9-10-EDA, and FNIII 9-10-11 
EDA (good agonists) were very similar. Finally, LPS endotoxin levels were tested in all 
the recombinant FN fragments and were found to be below 0.2 EU/µg in each. 
Considering the C-terminal context of FNIII EDA, the existence of a protease 
substrate was suggested between the FNIII EDA and FNIII 12 domains using a 
bioinformatic analysis32, specifically at the C-terminal end of FNIII EDA (position 87 of 
94 total). Experimentally, elastase 2 (neutrophil elastase) was observed to cleave 
between FNIII EDA and FNIII 12 (Fig. 1f), and cleavage was shown to enhance TLR4 
agonization compared to the intact control (Fig. 1g). Returning to the observation of 
the role of FNIII EDA and TLR4 in lesions such as in psoriasis10–12 and scleroderma15, 
which are characterized by neutrophil infiltration51,52, it may be that neutrophil-derived 
elastase-2-mediated proteolysis of FN to potentiate a cryptic TLR4-agonizing site is 
involved in the pathophysiological mechanism. 
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Although FN is present in the serum, its main biological activities are carried out 
in immobilized form as a component of the ECM. Thus, we also sought to investigate 
FNIII EDA’s immunological activity when immobilized in a matrix. As previously shown 
by our laboratory, recombinant proteins bearing an enzymatic substrate for the 
coagulation transglutaminase Factor XIIIa can be covalently incorporated into fibrin 
matrices53, a method that has proven to be an efficient delivery method for integrin 
ligands37 and growth factors in the context of tissue repair20,22,37. To determine whether 
FNIII EDA would induce similar reactions while presented in a more natural 
environment, we produced ECM-mimicking fibrin matrices functionalized with FNIII 
EDA-containing FN fragments and with the MHC I immunodominant peptide from 
OVA as a model antigen. In a first experiment aiming to test antigen-specific CD8+ T 
cell expansion, exposure to fibrin matrices functionalized with FNIII 11-EDA and TG-
OVA250-264 induced expansion (Fig. 2b) with more intense IFN-γ production upon re-
stimulation with antigen (Fig. 2d). Interestingly, the effect of the engineered matrix was 
comparable to that achieved by administration of OVA257-264 (which does not require 
antigen processing) adjuvanted with LPS (Fig. 2d). 
Surprisingly, fibrin matrices functionalized with FNIII 9-10-EDA induced 
significantly lower responses than matrices functionalized with both FNIII 11-EDA and 
FNIII 9-10. Such a difference may be due to FNIII 9-10-EDA’s tendency to precipitate 
at the concentrations used for the preparation of the fibrin matrices. These results show 
that FNIII EDA-rich ECM analogs can enhance a pre-established immune response at 
the level of antigen-specific CD8+ T cell expansion. 
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Because FNIII EDA has been shown to induce cellular immune responses 
including activation of CD8+ T cell responses, the domain in soluble form26–31 has been 
explored extensively as a cancer vaccine adjuvant in mouse models including when 
antigens are fused to it28,30,31, although most potently in combination with other TLR 
agonists28,31. Notably, when FNIII EDA-antigen fusions have been used as cancer 
vaccines, in conjugation with other TLR agonists, FNIII EDA has been used without N-
terminal extension and as a soluble protein (i.e. not linked to the ECM)28,30,31. Here, we 
employed tumor cell-killing assays to characterize the functionality of ECM-bound FNIII 
EDA’s effect upon CD8+ T cells to act as CTLs. Two models were utilized, one with a 
xenogeneic model tumor antigen, OVA (the E.G7-OVA thymoma model; Fig. 3 and 4), 
where the antigen is not centrally tolerized, and one with an endogenous tumor 
antigen TRP-2 (B16-F10 melanoma; Fig. 5), in which central tolerance must be 
overcome. The B16F10 melanoma model progresses very quickly, and as such the rate 
of tumor growth may outpace the rate of the adaptive immune response. In both 
models, administration of matrix-bound antigen (TG-OVA250-264 or TG-TRP-2173-188) with 
matrix-bound FNIII 11-EDA induced substantial delays in tumor growth, without any 
additional TLR agonists. Furthermore, while the addition of FNIII 9-10 did not improve 
the survival time of the mice, it nonetheless helped reduce the average tumor volume. 
Moreover, in the case of the E.G7-OVA model with repeated matrix implantation, 
complete tumor remission was observed in some instances (Fig. 4), however it is not 
known if the eventual escape in other animals from immune killing occurs via a bona 
fide immunological mechanism or due to selective pressure of vaccination toward 
antigenic selection leading to elimination of the OVA-encoding plasmid54,55. 
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To demonstrate that a prolonged presence of the FNIII EDA domain bound to 
the fibrin matrix was beneficial, the same molecules in soluble form were injected i.d 
(Fig. 3). This control route was chosen, because it allows for an efficient delivery of the 
vaccine to the same skin-draining lymph node as the tumor (in addition to other non-
affected lymph nodes) and thus maximizes the effect via a high percentage of targeted 
APCs being in contact with both the tumor antigens and the vaccine56. However, i.d. 
injection was much less effective in delaying tumor growth (Fig.3) compared to the 
fibrin matrix, clearly demonstrating that matrix binding of FNIII EDA fragment is 
beneficial. Furthermore, we judged the role of the inflammation from the surgical 
implantation of the matrix as being negligible, as FNIII-11-EDA-free matrices failed to 
provide protection against the tumor despite the presence of TG-OVA250-264 (Fig.3). 
Thus, using two tumor models, one with an exogenous model antigen and one with an 
endogenous antigen, N-terminally-extended FNIII EDA without C-terminal extension 
with the native FNIII 12-13-14 domain was shown to induce potent immunity as 
characterized by the cytotoxic functionality of induced CTLs when the FN domains were 
co-administered in a matrix with antigen. Moreover, the ability to kill the syngeneic 
melanoma demonstrates the ability to induce functional autoimmunity. 
Furthermore, in addition to exploring the ability of FNIII EDA to modulate 
immunity at the site of its presence, we explored effects in the spleen. The B16-F10 
model is known to be immune suppressive through induction of MO-MDSCs, which 
traffic between the tumor and the spleen57. Administration of fibrin matrixes presenting 
FNIII 11-EDA, FNIII 9-10 and TG-TRP2173-188 resulted in a substantial diminution of the 
frequency of MO-MDSCs in the spleen, demonstrating an ability to alter this immune 
suppressive mechanism (Fig. 5c). 
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In conclusion, these results bring insight into the immunological function of the 
FNIII EDA-containing FN splice variant in vivo. We revealed that the TLR4 agonizing 
potential of FNIII EDA is cryptic in FN, becoming exposed by cleavage between FNIII 
EDA and FNIII 12 by the neutrophil elastase 2. Lacking the C-terminal FNIII 12-13-14 
domain, TLR4 agonization was potentiated up to 5 fold. Moreover, by using two tumor 
growth models, we demonstrated that induction of CTL responses to a xeno- and an 
auto-antigen by FNIII EDA activity is enhanced when the domain is bound to an ECM 
analog. Therefore, because the FNIII EDA-containing splice variant is expressed in sites 
of chronic inflammation, autoimmunity, and in many tumors10–12, this ECM protein may 
contribute to the pathology and as well to an anti-tumoral benefit to the immune 
microenvironment by agonizing TLR4 especially after elastase-2-mediated proteolysis. 
In addition, delivering ECM-bound FNIII EDA fragments in combination with antigens 
could be an attractive option for anti-tumoral immunotherapies. 
 
2.5 Methods 
2.5.1 Recombinant proteins. 
All FN fragments were engineered to bear at their N-terminus the coagulation 
transglutaminase Factor XIIIa peptide substrate NQEQVSPL (TG) and were cloned in a 
pET-22b (+) (Novagen) plasmid between the restriction sites NdeI and NotI. This 
plasmid contains a 6xHis-tag being added at the 3’ end of the inserted genes. E. 
coli BL21DE3 were transformed and used for protein production. The recombinant 
proteins were purified using a HIStrap column (GE Healthcare) and washed using 0.1 
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% Triton X-100 in PBS for LPS removal and an ATP solution (2 mM ATP, 50 mM Tris-
HCl, 10 mM MgSO4, pH 7.4) for DnaK removal. An imidazole (1 M) buffer was used for 
elution. The proteins were then stored in TBS at -80°C. Endotoxin levels were tested by 
Quantitative Chromogenic Limulus Amebocyte Lysate and were below 0.2 EU/µg. 
 
 
2.5.2 Reagents. 
Ultrapure LPS Escherichia coli 0111:B4 was purchased from InvivoGen. Low 
endotoxin grade OVA (<0.01 EU/μg protein) was used for immunization (Hyglos). 
MHC-I H-2Kb immunodominant peptides OVA257–264 (SIINFEKL) and TRP-2180-188 
(SVYDFFVWL) were ordered from GenScript with the TG-sequence at their N-termini 
followed with N-terminal extension from the native protein OVA (SGLEQLE) 36 allowing 
proteolytic processing to liberate the epitopes (NQEQVSPLSGLEQLESIINFEKL, 
NQEQVSPLSGLEQLESVYDFFVWL). PE-labeled H-2Kb/OVA257–264 pentamer was 
purchased from ProImmune. Pentamer staining was performed according to the 
manufacturer’s instructions. 
 
2.5.3 Western blotting. 
FNIII 9-10-EDA-12-13-14 was first incubated with elastase 2 (Merck) at a 50:1 
ratio for 3 h at 37°C in PBS. SDS-PAGE (12% polyacrylamide gels) was then performed, 
followed by transfer to a nitrocellulose membrane. The membrane was then incubated 
either with an HRP-conjugated anti-6xHis (abcam) or with an anti-FNIII EDA (abcam, 
 58 
 
IST-9) antibody followed by an HRP-conjugated goat anti-mouse IgG1 secondary 
antibody (SouthernBiotech). After incubation, the blot was processed with SuperSignal 
West Pico Chemiluminescent Substrate (Pierce). 
 
2.5.4 In vitro stimulation of bone marrow-derived dendritic cells. 
Murine bone marrow-derived DCs were generated as described elsewhere58. On 
day 8, cells were plated at a density of 5 x 105 cells/well in 96-well plates and incubated 
overnight with 0.5 µM of recombinant proteins pre-incubated with 10 µg/ml of 
polymixin B to block interactions with any potentially contaminating LPS. Cytokines 
released in the supernatant were measured by ELISA (eBioscience). 
 
2.5.5 In vitro stimulation of HEK-Blue TLR4 cells 
HEK-Blue TLR4 LPS Detection Kit (Invivogen) containing HEK293 cells are 
engineered to express TLR4, MD2 and CD14 as well as a secreted embryonic alkaline 
phosphatase (SEAP) reporter gene controlled by an NF-κB-inducible promoter. HEK-
Blue TLR4 cells were plated at a density of 104 cells/well in 48-well plates and were 
cultured for 48 h until they were 80% confluent. They were then incubated overnight 
with 0.5 µM of recombinant proteins pre-incubated with 10 µg/ml of polymixin B. All 
protein solutions and an elastase 2 control were incubated 3 h at 37°C before 
stimulation. FNIII 9-10-EDA-12-13-14 + elastase 2 was prepared in a 50:1 ratio. After 
incubation, the supernatant was diluted 1:10 in HEKBlue Detection Medium (Invivogen) 
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and the expression of SEAP was measured by light absorption at 620 nm. Cell culture 
medium was DMEM + 10% FBS and assay medium was DMEM + 2 % FBS. 
 
2.5.6 In vitro stimulation of THP1-Blue cells. 
THP1-Blue cells (Invivogen) are human THP-1 monocyte cell line engineered to 
express an NF-κB-inducible SEAP reporter construct. THP1-Blue cells were plated at a 
density of 5 x 105 cells/well in 96-well plates and incubated overnight with two-fold 
serial dilutions of recombinant proteins pre-incubated with 10 µg/ml of polymixin B or 
LPS ranging from 0.012 µM to 12.5 µM and 0.06 ng/µl to 30 ng/µl, respectively. After 
incubation, the supernatant was diluted 1:10 in HEKBlue Detection Medium (Invivogen) 
and the expression of SEAP was measured by light absorption at 620 nm. Cell culture 
medium was RPMI 1640 (2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L 
glucose, 10 mM HEPES and 1.0 mM sodium pyruvate) with 10% heat inactivated FBS 
supplemented with 100 µg/ml of Zeocin and assay medium was RPMI 1640 + 2 % FBS. 
 
2.5.7 Mice and tumor cells. 
C57BL/6J mice (aged 7–8 wk) were purchased from Harlan Laboratories and kept 
under pathogen-free conditions at the animal facility of Ecole Polytechnique Fédérale 
de Lausanne. All experiments were performed in accordance with Swiss law and with 
approval from the Cantonal Veterinary Office of Canton de Vaud, Switzerland. E.G7-
OVA thymoma cells (i.e., EL4 cells (a thymoma line) expressing OVA as a surrogate 
tumor antigen, ATCC TIB-39) were obtained from American Type Culture Collection 
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(ATCC) and grown in RPMI medium 1640 (Invitrogen) supplemented with 10% heat-
inactivated FBS, 1 mM sodium pyruvate, 30 mM Hepes, 50 μM 2-mercaptoethanol, and 
0.4 mg/mL G418 antibiotic (Sigma). B16-F10 (ATCC CRL-2539) melanoma cells were 
obtained from American Type Culture Collection (ATCC) and were maintained in DMEM 
supplemented with 10% (vol/vol) FBS and penicillin/streptomycin/amphotericin B. 
 
2.5.8 Preparation of functionalized fibrin matrices. 
Fibrin matrices (150 µL) were formed by mixing a fibrinogen solution with a 
thrombin solution of equal volume in 1.5 mL Eppendorf tubes. The fibrin solution 
contained 16 mg/mL fibrinogen (plasminogen-, von Willebrand factor- and FN-
depleted; Enzyme Research Laboratories) in HEPES buffer (20 mM HEPES, 150 mM 
NaCl, pH 7.4). The thrombin solution contained, 2 U/mL human thrombin (Sigma–
Aldrich), 5 nmol of TG-OVA250-264 and/or 5 nmol of FNIII 11-EDA or FNIII 9-10-EDA, and 
5 mM Ca2+ in HEPES buffer. 
 
2.5.9 Stimulation of antigen-specific CD8+ response. 
C57BL/6J mice were immunized by injection in the four footpads with a total dose 
of 50 µg OVA and 20 µg LPS on day 0. On day 14, fibrin gels functionalized with 5 nmol 
of TG-OVA250-264 and 5 nmol of FNIII 11-EDA or FNIII 9-10-EDA were implanted s.c. on 
the back at the level of the shoulder girdle; alternatively mice were injected i.d. with 5 
nmol of OVA257-264 and 50 µg of LPS or plain PBS. On day 19 mice were sacrificed and 
the spleen was harvested. 
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2.5.10 Single-cell preparation and ex vivo antigen-specific cell 
restimulation. 
Splenocytes were obtained by squeezing the spleen with a razor blade and 
disrupting the cell aggregates on a cell sieve, washing thoroughly, and lysing the red 
blood cells. For CD8+ T cell antigen-specific restimulation and intracellular cytokine 
staining, immune cells were cultured at 37°C for 6 h in the presence of 1 μg/mL OVA257-
264 peptide. All cells were cultured in IMDM medium supplemented with 10% FBS and 
1% penicillin/streptomycin (all from Invitrogen). 
 
2.5.11 Flow cytometry and ELISA. 
Before antibody staining for flow cytometry, all cells were labeled with live/dead 
fixable cell viability reagent in PBS (Invitrogen). For surface staining, cells were 
incubated for 15 min with the antibodies diluted in HBSS (Invitrogen)/0.5% BSA (PAA 
Laboratories). For antigen specificity, cells were stained with a SIINFEKL:H2Kb MHC I 
pentamer (ProImmune). For intracellular cytokine staining, cells were fixed in 2% 
paraformaldehyde solution, washed with 0.5% saponin (Sigma-Aldrich) in HBSS/0.5% 
BSA solution, and incubated with the antibodies diluted in saponin solution for 30 min. 
After washing, cells were resuspended in HBSS/0.5% BSA solution for analysis. Samples 
were acquired on CyAn ADP Analyzer (Beckman Coulter) and data were analyzed with 
FlowJo software (Tree Star). The antibodies anti-mouse CD11c, CD62L, B220, CD44 and 
IFN-γ were purchased from BioLegend; anti-mouse CD3ε, CD8, CD11b, Ly6c, Ly6g, TNF-
α and MHC-II antibodies were purchased from eBioscience (San Diego, CA, USA). 
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Ready-SET-go! ELISA kits for cytokine detection were purchased from eBioscience and 
used according to manufacturer’s instructions. 
 
2.5.12 Tumor growth assays. 
Tumor cells were implanted s.c. in the back at the level of the junction between 
the thoracic and lumbar vertebrae of C57BL/6J mice with inoculation of 106 E.G7-OVA 
cells or 2.5 × 105 B16-F10 cells in 30 μL PBS (Invitrogen). The mice were then treated 
once (E.G7-OVA) or weekly for three weeks (E.G7-OVA and B16-F10) when their tumor 
reached 50 mm3 (E.G7-OVA) or when the tumor became visible (B16-F10). Fibrin gels 
(150 µl total, fibrinogen (8 mg/ml)) were functionalized with 5 nmol of FNIII domain 
recombinant proteins and with or without 5 nmol of MHC I immunodominant peptide 
bound to the fibrin, as described above. Tumors were measured 5 times per week and 
volumes were calculated as ellipsoids based on three orthogonal measures. Animal 
were killed either when the tumor reached 200 mm3 (B16-F10) or 1000 mm3 (E.G7-
OVA) or for humane reasons such as tumor necrosis, excessive loss of weight or evident 
isolation from the other animals. 
 
2.5.13 Statistical Analyses 
Statistical analyses were performed using Analysis of Variance (ANOVA) and 
Bonferonni posttest using GraphPad Prism. 
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2.6 Supporting Information 
 
 
Fig. S1 (a) SDS-PAGE analysis of the 6 different FNIII EDA-containing FN fragments 
produced.  (b) SDS-PAGE of FNIII 9-10-EDA-12-13-14 with or without prior incubation 
with thrombin or plasmin or a cocktail of MMP-2, MMP-3 and MMP-9 
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3.1 Abstract 
Safe and effective subunit vaccines require adjuvants with a correct balance 
between strong activation of the immune system and low toxicity for the patient. Here 
we hypothesize that combination of CpG, a bacterial TLR9 agonist, with the 
endogenous TLR4 agonist extra domain A type III repeat of fibronectin (FNIII EDA), 
which has shown the ability to induce cytotoxic CD8+ T cell responses in a non-toxic 
manner, would synergize to induce an efficient immune response while keeping the 
dose of the toxic CpG low. Here, we show that the combination of both adjuvants 
synergistically activates dendritic cells in vitro, induces a potent immune response 
sufficient to slow tumor growth in a murine tumor model and eradicates circulating 
hepatitis B virus in a transgenic HBV mouse model. 
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3.2 Introduction 
The success of vaccines over the last decades is undeniable, however several 
infectious diseases are still missing an effective vaccine, such as human 
immunodeficiency virus, malaria, and chronic hepatitis B, and a general approach to 
therapeutic cancer vaccination is still lacking. Subunit vaccines, employing purified 
protein antigens rather than intact pathogens, require the addition of adjuvants for 
enhanced immunogenicity1. The first compound used as an adjuvant, which is still 
widely used in human vaccination, is alum. Alum-based adjuvants have been shown to 
be efficient in inducing T helper (Th)2 responses2, leading to strong antibody secretion. 
Importantly, alum lacks the ability to induce potent cellular, Th1-biased responses, an 
important axis for fighting intracellular pathogens and cancer3. While adjuvants that 
are more potent than alum in inducing cell-mediated immunity have been developed, 
their application in clinic has been hindered by their toxicity and the systemic and local 
side effects they induce4.  
Hence, the development of safe and effective vaccines with fewer side effects 
remains a strong need5 and requires the development of a new generation of adjuvants 
with a correct balance between activating the immune system toward a balanced Th1 
and Th2 response, while maintaining low toxicity for the patient.  
Toll-like receptors (TLRs) are a preferential target for the development of novel 
adjuvants for improved vaccination strategies, as many of them induce adaptive 
cellular immunity, which is central for eliminating a wide variety of pathogens and 
fighting cancer6–9. Activating ligands have been identified for most of the 13 known 
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human TLRs, most of them stemming from bacterial or viral origins, but endogenous 
agonists have also been identified9. Among the various TLR ligands currently tested in 
clinical trials as adjuvants for vaccines, the TLR9 agonist unmethylated CpG 
oligodeoxynucleotide has been shown to induce potent B cell humoral responses and 
most importantly induce the maturation of DCs and the subsequent secretion of Th1-
biasing cytokines such as IL-12p70, IL-6 and TNF-α. Although reasonably safe at low 
dose10,11, increasing the dose of CpG when the targeted disease requires a stronger 
response has been associated with risks of toxic shock12. 
Recent studies on the use of the endogenous TLR4 agonist extra domain A type 
III repeat of fibronectin (FNIII EDA) as an adjuvant showed its ability to induce cytotoxic 
CD8+ T cell responses in a non-toxic manner in murine models13–15. Furthermore, our 
laboratory recently showed that the immunological activity of FNIII EDA was dependent 
of its molecular context and identified a more potent form of FNIII EDA N-terminally 
extended with the 11th type III repeat of FN (FNIII 11-EDA)13.  
Although single TLR targeting strategies have shown promising results11, some 
combinations of TLR-agonists are known to synergize, notably by their co-activation of 
the MyD88 and TRIF intracellular pathways, and induce responses that are greater than 
the sum of their individual effects16–20. Not just the strength, but most importantly the 
quality of the response induced by combined TLRs agonists has been increased20. As 
the signaling crosstalk of TLR4 and TLR9, which signal though MyD88 and TRIF for the 
former and MyD88 only for the later, has been shown to amplify the inflammatory 
response in mice21, we thus hypothesized that a combined administration of FNIII 11-
EDA and CpG could synergize and activate immune cells more efficiently than either 
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alone. This effect might allow a reduction of the total dose of adjuvant needed to 
induce an efficient immune response, thus lowering the inherent toxicity of CpG. 
Here, we first describe the synergistic pro-inflammatory cytokine secretion by 
dendritic cells (DCs) in vitro in response to the combination of FNIII 11-EDA and CpG. 
When injected in mice, ovalbumin (OVA) as a model antigen adjuvanted with combined 
half-doses of FNIII 11-EDA and CpG enhanced Th1 response and inflammatory 
cytokine secretion, both in CD4+ and in CD8+ T cells, compared to full doses of either 
CpG or FNIII 11-EDA. In addition, the proportion of antigen-specific CD8+ T cells was 
also marginally increased. Using an E.G7-OVA T cell lymphoma tumor model 
expressing the xeno-antigen OVA, we validated the synergistic effect of the 
combination of the two TLR ligands FNIII 11-EDA and CpG on the generation of 
functional cytotoxic T lymphocytes (CTLs) through the limitation of tumor growth and 
enhanced survival. 
Next, we sought to explore the ability of this TLR-agonist combination to break 
immune tolerance in a chronic hepatitis B transgenic mouse model expressing an 
hepatitis B virus (HBV) transgene (HBV-Tg mice)22,23, which makes the mice tolerant to 
the hepatitis B protein antigens. We show that immunization with the hepatitis B 
surface antigen (HBsAg), adjuvanted with a combination of half doses of CpG and FNIII 
11-EDA, was able to trigger an efficient Th1 immune response both in the spleen and 
the liver, a subsequent higher rate of HBsAg seroconversion, and more efficient 
clearance, highlighting a better Th1 cytokine secretion profile compared to full doses 
of the individual ligands. 
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3.3 Results 
3.3.1 FNIII 11-EDA and CpG activate DCs in a synergistic manner 
To determine whether FNIII 11-EDA and CpG were able to synergistically activate 
DCs, binomial combinations of both adjuvants were tested in vitro (Fig. 1) and the 
activation of DCs was evaluated by quantifying the production of the pro-inflammatory 
cytokines IL-12p70, IL-6 and TNF-α by ELISA. Although FNIII 11-EDA or CpG alone 
induced only mild activation of DCs at the doses tested (up to 2 µM each CpG and FNIII 
11-EDA), their combination led to a synergistic increase in the production of IL-12p70 
(Fig. 1a), IL-6 (Fig. 1b), and TNF-α (Fig. 1c). Indeed, the combination of both TLR 
agonists resulted in more than twice the expected theoretical amount of cytokine 
secreted for most concentration combinations tested. 
 
Figure 1. CpG and FNIII 11-EDA show synergistic activation of dendritic cells and 
stimulate strong IL-12p70, IL-6 and TNF-α production. In vitro, DCs secreted higher 
amounts of IL-12p70 (a) and IL-6 (b) TNF-α (c) when stimulated overnight with binary 
combination of FNIII 11-EDA and CpG (main squares) than the expected theoretical 
sum of both separated ligands (diamonds, sum of each individual ligand cytokine 
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secretion). Data shows ELISA readouts of measured from two independent experiments 
and expected cytokine concentration as heat maps; color scales are indicated. 
 
3.3.2 Intradermal co-immunization with FNIII 11-EDA and CpG 
induces potent Th1 response and increases cytotoxic activity 
of antigen-specific CD8+ T cells 
After observing that the two TLR agonists FNIII 11-EDA and CpG led to a 
synergistic activation of DCs in vitro, we proceeded to evaluate their ability to synergize 
towards mounting a potent antigen-specific response in vivo in an OVA prime-boost 
vaccination mouse model. Mice were immunized by intradermal injections with the 
model xeno-antigen OVA co-delivered with FNIII 11-EDA and/or with CpG on days 0 
and 14 (Fig. 2a). To assess the potential synergy, effects of 5 nmol FNIII 11-EDA or 40 
µg CpG were compared to the effect of the combination of half-doses of both TLR 
agonists together.  
Both vaccinating with full-dose CpG and with the combination of both adjuvants 
at half-doses induced significant levels of SIINFEKL-MHCI-specific pentamers+ CD8+ T 
cells (SIINFEKL being the MHCI binding immunodominant peptide of OVA), while a full 
dose of FNIII 11-EDA had no observable effect. Combination of both adjuvants induced 
marginally higher levels of OVA-specific CD8+ T cells compared to CpG alone (Fig. 2b) 
and significantly higher frequency of IFN-γ+ TNF-α+ CD4+ T cells following ex vivo 
restimulation with OVA (Fig. 2c). Moreover, after restimulation of splenocytes with the 
SIINFEKL peptide (Fig. 2d,e), the CD8+ T cell population induced by the simultaneous 
administration of both adjuvants at the half doses showed a significantly enhanced 
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effector phenotype as shown by the higher frequency of IFN-γ producing CD8+ T cells 
both in the total population of CD8+ T cells (Fig. 2d) and degranulating LAMP1+CD8+ T 
cells (Fig. 2e). The half dose of CpG used in combination with half-dose of FNIII 11-EDA 
was also able to achieve a comparable level of production of IFN-γ by splenocytes 
restimulated for 3 days with OVA to that obtained with a full dose of CpG (Fig. 2f).  
 
Figure 2. FNIII 11-EDA and CpG are effective at inducing antigen-specific CD8+ T 
cell and Th1 responses. (a) Immunization schedule. C57BL/6J mice were immunized 
by intradermal injection in the four footpads with 50 µg of OVA adjuvanted with 40 µg 
of CpG or 5 nmol of FNIII 11-EDA or 20 µg of CpG plus 2.5 nmol of FNIII 11-EDA on 
day 0. On day 14, mice were injected with the same formulations as on day 0. On day 
19, mice were sacrificed and the spleens were harvested. (b) Injection of 50 µg of OVA 
adjuvanted with combined 20 µg of CpG and 2.5 nmol of FNIII 11-EDA induced levels 
of SIINFEKL-MHC-I-specific CD8+ T cells in the spleen comparable to that induced of 
50 µg of OVA adjuvanted with 40 µg of CpG. (c) Frequency of IFN-γ+TNF-α+ CD4+ 
splenocytes after 6 h ex vivo restimulation with OVA were evaluated by flow cytometry. 
The proportion of IFN-γ+ TNF-α+ CD4+ T cells was also significantly improved by 
simultaneous injections of half doses of CpG and FNIII 11-EDA compared to full doses 
of each adjuvant alone. (d,e) Frequencies of IFN-γ+ and IFN-γ+ LAMP1+ CD8+ 
splenocytes after 6 h ex vivo restimulation with SIINFEKL were evaluated by flow 
cytometry. The frequency of IFN-γ producing CD8+ T cells was significantly improved 
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(d) by simultaneous injections of half doses of CpG and FNIII 11-EDA compared to full 
doses of each adjuvant alone. (e) Similarly, the frequency of IFN-γ+ LAMP1+ CD8+ T 
cells was significantly higher when both adjuvants were used. (f) IFN-γ production from 
splenocytes restimulated for 3 days ex vivo with OVA was evaluated by ELISA. Here, 
injection of half-doses of both adjuvants only marginally improved the production of 
IFN-γ compared to a full dose of CpG. Box plots represent means ± 95% confidence 
interval (n = 5). *, # P < 0.05; **, ## P < 0.01; ### P<0.001; ns, not significant; #, ##, 
###, comparison to naïve group. 
 
3.3.3 Injections of OVA adjuvanted with CpG plus FNIII 11-EDA 
mediate regression of E.G7-OVA tumor through functional 
cytotoxic T lymphocyte response  
To determine the level of functionality of CD8+ T cells generated after 
immunization with antigen combined with CpG and FNIII 11-EDA, the E.G7-OVA T cell 
lymphoma tumor model expressing OVA as a surrogate antigen was used. Tumor cells 
were injected subcutaneously (s.c.) in the back of mice and tumors were let grow until 
reaching a volume of 50 ± 5 mm3, at which point treatments with OVA alone, OVA 
adjuvanted with CpG and/or FNIII 11-EDA, or saline were initiated and a second 
treatment dose injected 6 days later. Similarly to the previous experiment, OVA was 
injected with either 40 µg of CpG, 5 nmol of FNIII 11-EDA or both adjuvants combined 
at half-doses to assess synergistic activation. OVA was also injected with a half dose of 
CpG in the absence of FNIII 11-EDA to explore the extent to which response in the 
combined adjuvant group might be due to CpG alone. Tumor sizes were followed daily 
and used as an indication for CD8+ T cell functionality.  
Tumor regression was observed both in response to OVA combined with full-
dose CpG and half-doses of combined CpG + FNIII 11-EDA as shown on average (Fig. 
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3a) and individual (Fig. 3b) tumor growth curves. Both groups temporarily showed 
examples of complete tumor regression, although this was more common when both 
adjuvants were co-administered. Tumor growth resumed faster when CpG at the full 
dose was used alone, whereas in mice treated with the combination of CpG and FNIII 
11-EDA even at the half dose the treatment exerted control over tumor growth for a 
longer period of time. Only 2 out of 10 animals vaccinated with CpG alone survived 
longer than 25 days, while 7 out of 9 animals treated with CpG and FNIII 11-EDA even 
at the half dose survived longer than 30 days, with complete tumor remission in 3 out 
of 9 cases as shown by the Kaplan-Meier survival curves (Fig. 3c). OVA alone or 
supplemented with full-dose FNIII 11-EDA had only a mild effect on tumor growth. In 
support of the synergistic effect of FNIII 11-EDA and CpG, vaccination with OVA with 
the half-dose of CpG without co-administration of FNIII 11-EDA also had only a mild 
effect on tumor growth.  
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Figure 3. Multiple injections of OVA adjuvanted with both CpG and FNIII 11-EDA 
mediate regression of E.G7-OVA tumors. C57BL/6J mice were injected s.c. with 106 
E.G7-OVA cells on the back. Mice were then treated with OVA or OVA adjuvanted either 
with combined half doses of CpG and FNIII 11-EDA or with full doses of each adjuvant 
alone or with a half dose of CpG without FNIII 11-EDA when their tumor reached 50 ± 
5 mm3 and received a second injection of the treatment 6 days later. Mice were 
sacrificed when the tumor reached 1000 mm3 or for humane reasons. Tumor regression 
and growth delay were significantly improved in animals treated with combined 
adjuvants both in terms of tumor volume (a) and animal survival (b). Individual growth 
curves (c) show regression in most of the animals treated with both adjuvants although 
in most of them tumor growth eventually resumed. The values corresponding to the 
animal which died were kept as a constant until the curves were stopped. Growth 
curves represent mean ± SEM; Kaplan-Meier survival-curves (n = 4-10) from two 
independent experiments. *** P<0.001.  
 
3.3.4 Co-immunization with HBsAg adjuvanted with FNIII 11-EDA 
and CpG leads to strong Th1 cytokine secretion and HBsAg 
seroconversion 
To explore the ability of the CpG plus FNIII 11-EDA to break immune tolerance, 
we employed a HBV-Tg mouse model tolerant to the hepatitis B protein antigens and 
expressing the HBV in the liver and kidney22. Mice were vaccinated on day 0 and 14 by 
i.d. injection of HBsAg alone, HBsAg supplemented with CpG and/or FNIII 11-EDA, or 
saline as control. Mice were sacrificed on day 19 and blood, liver and spleen was 
harvested for ex vivo restimulation, ELISA and determination of viral load (Fig. 4a). To 
assess synergistic activation of the immune system in response to the TLR agonists, 
effects of 80 µg of CpG or 10 nmol of FNIII 11-EDA were compared to the half-dose of 
both adjuvants combined. Here the dose of each adjuvant was doubled compared to 
tumor experiment, as preliminary experiments with this model showed that relatively 
high doses were required. 
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After restimulation of splenocytes for 6 h with HBsAg ex vivo (Fig. 2b,c), a 
significant increase in the frequency of Th1 cytokine-secreting CD4+ T cells was 
observed in response to co-vaccination with CpG and FNIII 11-EDA at the half dose 
(Fig. 4b) compared to CpG or FNIII 11-EDA alone at the full dose. However, the 
frequency of CD8+ T cell secreting IFN-γ was higher when CpG was used as the only 
adjuvant (Fig. 4c). Ex vivo restimulation of liver cells with HBsAg for 6 h showed that 
vaccination with both adjuvants combined also increased the frequency of Th1 
cytokine-secreting CD4+ T cells compared to CpG alone, although FNIII 11-EDA alone 
unexpectedly showed a comparably high frequency (Fig. S1b). No difference in IFN-γ-
secreting CD8+ T cells populations in the liver was observed between the different 
treated groups (Fig. S1c). Co-immunization with CpG and FNIII 11-EDA slightly 
increased the level of production of IFN-γ by splenocytes (Fig. 4d) and liver cells (Fig. 
S1d) after restimulation for 3 days with HBsAg, although in most cases high variability 
prevented to reach statistical significance between groups. 
We then evaluated the level of circulating HBsAg in the blood sampled at day 19, 
which is an indication of the elimination of virally-produced HBsAg by elicited 
antibodies secreted by the vaccine formulation, and of a limitation of the replication of 
the virus. Here all three treatment formulations, i.e. full-dose FNIII 11-EDA, full-dose 
CpG and combined half-doses of each adjuvant, significantly reduced the amount of 
circulating HBsAg in blood (Fig. 4e). The combination of half doses of each adjuvant 
significantly improved the elimination of the virally-produced protein compared to full-
doses of each adjuvant alone. It is noteworthy that a half-dose of CpG without the 
addition of FNIII 11-EDA was not sufficient to achieve significant reduction of the 
amount of circulating HBsAg (Fig. S1e), demonstrating the synergistic response. Finally, 
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endpoint titers of anti-HBsAg IgGs were all significantly higher than control in all 
groups. The combination of CpG and FNIII 11-EDA yielded significantly higher titers 
than the other responding groups, while naïve mice showed no detectable level of anti-
HBsAg antibodies (Fig. 4f). 
 
Figure 4. Co-injection of HBsAg adjuvanted with the two TLR agonists CpG and 
FNIII 11-EDA leads to enhanced production of inflammatory cytokines by T cells 
and HBsAg seroconversion. (a) Immunization schedule. HBV-Tg mice were 
immunized by intradermal injection in the four footpads with 10 μg HBsAg adjuvanted 
with 80 µg of CpG or 10 nmol of FNIII 11-EDA or 40 µg of CpG and 5 nmol of FNIII 11-
EDA on day 0 and day 14. On day 19 mice were sacrificed and spleens, livers and blood 
were collected. (b,c) Frequency of IFN-γ+TNF-α+ splenocytes restimulated for 6 h ex 
vivo with HBsAg were evaluated by flow cytometry. The proportion of CD4+ T cells 
producing IFN-γ and TNF-α was significantly improved by co-injection of half doses of 
both TLR agonists although a full dose of CpG alone yielded a higher amount of IFN-
γ+ CD8+ T cells. (d) Magnitude of IFN-γ production from splenocytes restimulated ex 
vivo for 3 days with HBsAg were evaluated by ELISA; injection of half-doses of both 
adjuvants only marginally improved the production of IFN-γ compared to a full dose 
of CpG. (e) The concentration of HBsAg in the blood, as determined by ELISA (optical 
density), was significantly reduced in mice receiving the combinations of both 
adjuvants although all treatments were able to reduce the HBsAg concentration to 
some extent. (f) Endpoint titers of anti-HBsAg IgGs were all significantly higher than 
control in all groups. The combination of CpG and FNIII 11-EDA yielded the highest 
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titers of the responding groups. Naïve mice had no detectable level of anti-HBsAg IgGs. 
Box plots represent means ± 95% confidence interval (n = 8) from two independent 
experiments. *P < 0.05; **P < 0.01; ns, not significant; ##, ###, comparison to naïve 
group. 
 
3.4 Discussion 
Although the benefits of adjuvants towards improved vaccination safety and 
efficacy are indisputable, the perfect balance between activation of the immune system 
and side effects remains somewhat elusive. A possible strategy to achieve this desired 
balance would be the optimization of TLR agonist-based adjuvants24. In that regard, 
exploiting the ability of given pairs of TLR agonists to synergize to induce a stronger 
immune responses18,20 would allow reduction of the amount of the adjuvant used in 
the vaccine. The TLR9 ligand CpG has proven to be an effective adjuvant10 although 
safety issues arise when used at high doses12. The TLR4 agonist FNIII EDA and its variant 
FNIII 11-EDA, although not as strong as CpG, have nonetheless showed their ability to 
induce functional CD8+ T cell responses without toxicity13–15. As co-activation of TLR4 
and TLR9 has proved to be a promising immunotherapy strategy21,25, we thus 
hypothesized that the combination of FNIII 11-EDA and CpG would induce an 
enhanced immune response while allowing the dose of the exogenous CpG to be kept 
at a low level.  
In this study, we first wanted to verify the ability of CpG and FNIII 11-EDA to 
activate DCs in a synergistic manner (Fig. 1). Our results indeed show that activation of 
DCs was greatly enhanced in response to the co-stimulation with both adjuvants 
compared to stimulation with each of them separately, as shown by the secretion of 
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IL-12p70 (Fig. 1a), IL-6 (Fig. 1b) and TNF-α (Fig. 1c). The measured cytokines levels were 
frequently at least twice as high as sum of the values obtained by each TLR agonist 
alone, with near to 10-fold increases being observed for some combinations. These 
results are interesting as TLR synergies have been reported to rely heavily on activation 
of the TRIF and MyD88 pathways17. Although FNIII EDA constructs induce the 
production of TNF-α13, which expression is strictly MyD88-dependent26, the ability of 
FNIII 11-EDA to synergize with a TLR9 ligand indicate that the TRIF pathway is also 
probably activated. This suggests that FNIII 11-EDA signals through both TRIF and 
MyD88 and would have the potential to synergize with most TLR ligand19. 
To determine whether CpG and FNIII 11-EDA would synergize in vivo and induce 
an enhanced antigen-specific CD8+ T cell response, we used OVA as a model antigen 
in a vaccination study. Effects of immunization with OVA alone, OVA adjuvanted with 
either full-dose CpG, full-dose of FNIII 11-EDA or combined half-doses of both 
adjuvants were compared (Fig. 2). Interestingly, combination of half doses of CpG and 
FNIII 11-EDA was able to induce a comparable amount of antigen-specific CD8+ T cells 
to that obtained with a complete dose of CpG (Fig. 2b), while also leading to a higher 
quality response, as shown by the enhanced effector phenotype observed (Fig. 2c-e). 
Moreover it is especially remarkable that after ex vivo restimulation, the Th1-cytokine 
expression profile of CD4+ T cells (Fig. 2c) induced by the combined half-doses was 
more than two-fold higher than the sum of the average frequency obtained with full 
doses of each adjuvant alone. A similar observation can be made on the average 
frequency of IFN-γ expressing-CD8+ T cells (Fig. 2d,e) although these differences were 
much attenuated when observing secretion of IFN-γ from the total splenocytes 
population after 3 days of restimulation (Fig. 2f). These results show that the in vitro 
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observations of synergy between CpG and FNIII 11-EDA can be translated in vivo to 
induce a stronger or at least equivalent immune response while reducing the dose of 
CpG. 
Both CpG and FNIII 11-EDA have shown separately their ability to induce efficient 
cellular immune responses in cell-killing assays13,27. Here we used the E.G7-OVA T cell 
lymphoma model to assess their ability to synergize to induce an effective anti-tumor 
CD8+ T cell response (Fig. 3). In this experiment, full doses of each adjuvant used 
separately were again compared to combined half-doses of both in their ability to 
control the growth of pre-established tumors. The half-dose of CpG without FNIII 11-
EDA and full-dose FNIII 11-EDA used alone only slightly slowed tumor growth. Full 
dose CpG alone induced tumor regression, however growth resumed in all animals and 
none of them survived longer than 29 days. The majority of mice treated with both 
adjuvants together, however, lived longer than 33 days with one-third showing 
complete remission. It is also noteworthy that the tumor of more than half of the 
animals treated with both adjuvants temporarily regressed to undetectable levels 
before resuming growth, whereas only one out of ten tumors treated with CpG alone 
regressed to that level. It is possible that tumor escape in these animals was due to 
selective pressure leading to the appearance of OVA-free tumors cells28. In addition, it 
would be of interest to determine if increasing the number of injections would lead to 
complete remission of mice in the group treated with both adjuvants, as animals in 
these studies were treated only twice.  
To demonstrate whether the cellular response induced by this synergy was 
sufficiently strong to overcome immune  tolerance, we used HBV-Tg mice, which 
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express HBV and in which HBsAg, among others, is tolerized22,23. Here the total dose of 
each adjuvant was doubled compared to previous experiments, although the 2:1 ratio 
was conserved for single versus dual adjuvant comparison. In this model, the 
combination of CpG and FNIII 11-EDA enhanced the Th1 profile of the immune 
response both in the spleen and in the liver (Fig. 4b, S1b) compared to CpG, even 
though the frequency of expressing IFN-γ CD8+ T cells was unexpectedly significantly 
lower than that induced by CpG alone. However, such expression of IFN-γ was 
seemingly not antigen-specific, as unstimulated splenocytes showed similar results. 
Nevertheless, an antigen specific response was achieved as shown by the significantly 
reduced level of circulating HBsAg in the blood in mice treated with both adjuvants 
together compared to those treated with a single adjuvant (Fig. 4e). The fact that 
complete seroconversion was not achieved can be explain by the fact that HBV is 
replicated from an integrated transgene, which cannot be eliminated23. It is also 
interesting to note that a half dose of CpG used without FNIII 11-EDA was not sufficient 
to induce a significant reduction of the level of circulating HBsAg as shown in figure 
S1. Recent studies have demonstrated that the use of a second antigen, namely 
hepatitis B core antigen (HBcAg) was leading to stronger responses due to B cells 
help29. This strategy could further enhance our formulations. 
Together these results clearly show that CpG and FNIII 11-EDA have the ability 
to synergize to break T cell tolerance and induce an enhanced antigen specific 
response. It is important that these improved effects were obtained while lowering the 
total dose of the foreign agent CpG, opening the door to the development of potent 
immunotherapies with fewer side effects and improved safety. 
 86 
 
3.5 Methods 
3.5.1 Reagents  
Chemicals were obtained from Sigma-Aldrich. Low endotoxin grade OVA (<0.01 
EU/μg protein) was used for immunization (Hyglos). PE-labeled H-2Kb/SIINFEKL 
pentamer was purchased from ProImmune. Pentamer staining was performed 
according to the manufacturer’s instructions. CpG type-B 1826 oligonucleotide (5’-
TCCATGACGTTCCTGACGTT-3’) was purchased from Microsynth AG, and HBsAg from 
Prospec-Tany TechnoGene Ltd. 
 
3.5.2 Recombinant proteins  
FNIII 11-EDA fragment was cloned in a pET-22b (+) (Novagen) plasmid between 
the restriction sites NdeI and NotI. This plasmid contains a 6xHis-tag being added at 
the 3’ end of the inserted genes. E. coli BL21DE3 were transformed and used for protein 
production. The recombinant proteins were purified using a HIStrap column (GE 
Healthcare) and washed using 0.1 % Triton X-100 in PBS for LPS removal and an ATP 
solution (2 mM ATP, 50 mM Tris-HCl, 10 mM MgSO4, pH 7.4) for DnaK removal. An 
imidazole (1 M) buffer was used for elution. The proteins were then stored in tris-
buffered saline (TBS) at -80 °C. Endotoxin levels were tested by Quantitative 
Chromogenic Limulus Amebocyte Lysate and were below 0.2 EU/µg. 
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3.5.3 In vitro stimulation of bone marrow-derived dendritic cells  
Murine bone marrow-derived DCs were generated as described elsewhere58. On 
day 8, cells were plated at a density of 5 x 105 cells/well in DMEM supplemented with 
10 % foetal bovine serum (FBS) and 1 % penicillin/streptomycin (PS) in 96-well plates. 
DCs were incubated for 6 h with 0, 0.5, 1 or 2 µM of CpG and/or recombinant FNIII 11-
EDA. To block interactions with any potentially contaminating LPS, FNIII 11-EDA was 
pre-incubated with 10 µg/ml of polymixin B. Cytokines released in the supernatant 
were measured by ELISA (eBioscience). 
 
3.5.4 Flow cytometry and ELISA  
Blood was collected from the tail vein, and serum was separated by 
centrifugation and stored at -20 °C. Viable cells were detected by LIVE/DEAD (L/D) 
Fixable Aqua stain (Invitrogen) and the following antibodies were used for surface and 
intracellular staining: CD3ε Pacific Blue, CD4 FITC, CD8 APC-Cy7, IFN-γ APC, LAMP1 PE, 
TNF-α PE (eBioscience). For staining of blood, splenocytes, and liver cells, cells were 
exposed for 5 min at RT to 0.155 M NH4Cl to lyse erythrocytes. The following staining 
steps were performed on ice. Cells were washed with PBS, stained for 15 min with Aqua 
L/D stain, resuspended in PBS with 2 % FBS for surface staining for 15 min and finally 
fixed for 15 min in PBS + 2 % PFA. IFN-γ intracellular staining was performed in PBS + 
2 % FBS supplemented with 0.5 % Saponin. For antigen specificity, cells were stained 
with a SIINFEKL:H2Kb MHC-I pentamer (ProImmune). Flow cytometry measurements 
were performed using a CyAn ADP Analyzer (Beckman Coulter). Detection of HBsAg 
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and IFN-γ were performed using an HBsAg ELISA kit (AMS biotechnology, Abingdon, 
UK) and a Ready-Set-Go ELISA Kit (eBioscience), respectivel according to the 
manufacturers protocol. 
 
3.5.5 Mice 
C57BL/6J mice (aged 7-8 wk) were purchased from Harlan Laboratories (France). 
Chi 1.3.32 (line 1.3.32, on a C57BL/6J background) mice (HBV-Tg, aged 7-10 wk) 
replicating a 1.3 equivalent complete HBV genome were kindly provided by Dr. Didier 
Trono (Ecole Polytechnique Fédérale de Lausanne, EPFL)22.  These mice replicate the 
virus at high levels in the liver and kidneys. As well, the levels of circulating HBsAg and 
viral particles in the serum of these mice are comparable to chronically infected 
humans. Both types of mice were kept under pathogen-free conditions at the animal 
facility of EPFL. All experiments were performed in accordance with Swiss law and with 
approval from the Cantonal Veterinary Office of Canton de Vaud, Switzerland. 
 
3.5.6 In vivo antigen-specific T cell response  
C57BL/6J mice were immunized by intradermal injection in the four footpads with 
a total dose of 50 µg OVA adjuvanted with 40 µg of CpG (referred to as full-dose CpG) 
or 5 nmol of FNIII 11-EDA (referred to as full-dose FNIII 11-EDA) or 20 µg of CpG and 
2.5 nmol of FNIII 11-EDA combined on day 0 and day 14. On day 19 mice were 
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sacrificed and the spleen harvested for ex vivo restimulation and flow cytometry 
staining.  
 
3.5.7 Ex vivo antigen-specific cell restimulation  
Liver immune cells were isolated from hepatocytes by low speed spins, and debris 
were removed using a 37.5 % Percoll® (GE Healthcare) gradient. Splenocytes and liver 
cells were exposed for 5 min at RT to 0.155 M NH4Cl to lyse erythrocytes. For antigen-
specific restimulation, immune cells were cultured in vitro at 37 °C for 6 h in the 
presence of 40 μg/mL of HBsAg or 100 μg/mL of OVA in supplemented with 10 % FBS 
and 1 % PS (all from Invitrogen). After 3 h of in vitro restimulation, Brefeldin-A (5 μg/mL) 
was added and intracellular cytokine production was assessed by flow cytometry. 
Antigen-specific restimulation was also carried out over 3 days for measurement of 
secreted cytokines by ELISA. 
 
3.5.8 Tumor growth assays  
Tumor cells were implanted s.c. in the back at the level of the junction between 
the thoracic and lumbar vertebrae of C57BL/6J mice with inoculation of 106 E.G7-OVA 
cells in 30 μL PBS (Invitrogen). The mice were then treated when their tumor reached 
50 ± 5 mm3 and received a second injection of the treatment 6 days later. Mice were 
immunized by injection in the four footpads with a total dose of 50 µg OVA adjuvanted 
with 40 µg of CpG (referred to as full-dose CPG) or 5 nmol of FNIII 11-EDA (referred to 
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as full-dose FNIII 11-EDA) or 20 µg of CpG and 2.5 nmol of FNIII 11-EDA or 20 µg of 
CpG alone withoutFNIII 11-EDA. Tumors were measured 5 times per week and volumes 
were calculated as ellipsoids based on three orthogonal measures. Animal were killed 
when the tumor reached 1000 mm3 or for humane reasons such as tumor necrosis, 
excessive loss of weight or evident isolation from the other animals in accordance with 
Swiss regulations. 
 
3.5.9 Immunization of HBV-Tg mice 
All experiments carried out with HBV-Tg mice were performed in P2 and P3 
biosafety levels. Intradermal immunizations of mice were performed in the four 
footpads. Vaccine contained 10 μg HBsAg in 100 µl PBS adjuvanted with 80 µg of CpG 
(referred to as full-dose CpG) or 10 nmol of FNIII 11-EDA (referred as full-dose CpG) or 
40 µg of CpG and 5 nmol of FNIII 11-EDA. Mice were immunized twice, on days 0 and 
14. Mice were sacrificed on day 19 and blood, liver and spleen collected for ex vivo 
restimulation and flow cytometric analysis. 
 
3.5.10 Data Analysis  
All flow cytometry data were analyzed using FlowJo (TreeStar Inc.). Graphing 
and statistical analyses of worked-up data were performed using GraphPad Prism v.5. 
1-way ANOVA with Bonferroni post-test was used for interpreting flow cytometry and 
ELISA data (***P < 0.001; **P < 0.01; *P < 0.05). 
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3.6 Supporting Information 
 
Figure S1. (a) Immunization schedule. HBV-Tg mice were immunized by intradermal 
injection in the four footpads with 10 μg HBsAg adjuvanted with 80 µg of CpG or 10 
nmol of FNIII 11-EDA or 40 µg of CpG and 5 nmol of FNIII 11-EDA on day 0 and day 
14. On day 19, mice were sacrificed and spleens, livers and blood were collected. (b) 
Frequencies of IFN-γ+TNF-α+ CD4+ T cells from liver restimulated ex vivo for 6 h with 
HBsAg were evaluated by flow cytometry. Here the proportion of CD4+ T cells 
producing IFN-γ and TNF-α was significantly improved by co-injection of half doses 
of both TLR agonists compared to a full dose of CpG alone although a full dose of 
FNIII 11-EDA yielded a comparable frequency of IFN-γ+TNF-α+ CD4+ T cells. (c) 
Frequencies of IFN-γ+ CD8+ T cells restimulated for 6 h ex vivo with HBsAg were 
evaluated by flow cytometry (d) Magnitudes of IFN-γ production from liver T cells 
restimulated ex vivo for 3 days with HBsAg were evaluated by ELISA; injection of half-
doses of both adjuvants only marginally improved the production of IFN-γ compared 
to a full dose of CpG. (e) A separate experiment where mice were vaccinated 
following the same schedule but with only 40 µg of CpG or 20 µg of CpG and 2.5 
nmol of FNIII 11-EDA shows that 40 µg of CpG alone is not sufficient to achieve a 
HBsAg seroconversion. Box plots represent means ± 95% confidence interval (n = 8). 
*P < 0.05;  **P < 0.01; ns, not significant;  ##, ###, comparison to naïve group. 
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Chapter 4 
 
 
The Extra Domain A of Fibronectin acts 
as a growth factor-binding domain; 
impairs wound healing 
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4.1 Abstract 
Fibronectin (FN) is an essential multidomain protein of the extracellular matrix 
(ECM) essential for numerous ECM-dependent processes. A splice variant of FN, the FN 
type III repeat extra domain A (FNIII EDA) still shows some functions that are not yet 
fully elucidated. Here, by screening a variety of growth factors (GF) and cytokines, we 
showed that FNIII EDA and its variant FNIII 11-EDA have the ability to bind certain 
signaling molecules, with PDGF-AA showing the strongest affinity. We then tested the 
ability of the FNIII 11-EDA-PDGF-AA complex to modulate fibroblasts proliferations 
and differentiation, suggesting a potential mild synergy between the two proteins. 
Finally, using a skin wound model, we explored how fibrin matrices functionalized with 
FNIII 11-EDA-containing FN fragments influence tissue repair outcome. 
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4.2 Introduction 
Fibronectin (FN) is an essential component of the extracellular matrix (ECM). This 
multidomain glycoprotein is crucial in numerous ECM-dependent processes such as 
cell adhesion, migration, growth, and differentiation1, with certain functions depending 
on the presence of the alternatively spliced type III repeat extra domain A (FNIII EDA). 
This alternatively spliced isoform of FN which is expressed during embryogenesis2,3 , 
within tumors4,5, at sites of chronic inflammation6–8 or in response to tissue damages9,10, 
is known to bind integrins α9β1, α4β1 and α4β710–12 and agonize Toll-like receptor 4 
(TLR4)13,14, however some functions of FNIII EDA are not yet fully elucidated. 
Previous researches from our laboratory showed that FN binding could modulate 
the activity of GFs15 and cytokines16. Interestingly, FNIII 12-13-14, which has been 
shown to have the ability to modulate the effects of vascular endothelial growth factor-
A (VEGF-A) and platelet-derived growth factor (PDGF)-BB and bone morphogenetic 
protein-2 (BMP-2)15, is the C-terminal neighboring domain of FNIII EDA (Fig. 1). 
Furthermore in addition to be FNIII EDA’s expression sites, wounds and inflammation 
microenvironments17 rich in GFs and cytokines,  suggesting that FNIII EDA could 
modulate the activity of bound signaling proteins upon FN splicing. Moreover FNIII 
EDA is known to actively modulating the healing process18 at sites of injury as skin 
wound healing in FNIII EDA-/- mice was shown to be abnormal19, however its precise 
role within the healing process remains poorly understood. 
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Fig. 1. Fibronectin structure.  FNIII EDA-containing FN fragments produced and 
full length FN with some of its interaction sites displayed 
 
Even though other domains of FN have been shown to bind growth factors 
(GF)15,20 and cytokines16 the ability of FNIII EDA to do so remains unexplored. Here we 
tested the binding of a wide library of GFs and cytokines to FNIII EDA. In order to 
represent more accurately the in vivo situation we also used a form of FNIII EDA N-
terminally extended with the anastellin-binding21 FNIII 11, FNIII 11-EDA, as FNIII EDA 
can be truncated at its C-terminus22 (Chapter 2) but not at its N-terminus.  Based on 
the results from the binding assays we then evaluated the ability of FNIII 11-EDA-GFs 
complexes to modulate fibroblasts proliferation and differentiation.  
Finally, in order to better understand the role and function of FNIII EDA during 
tissue repair we used a skin wound model and treated the wounds with functionalized 
fibrin matrices creating a FNIII 11-EDA-rich microenvironment.  As we showed in a 
previous study, the ability of FNIII EDA to agonize TLR4 is cryptic22 and relies on a 
proteolytic cleavage by elastase 2 at its C-terminus to release its activity. We therefore 
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sought to understand whether any observed effect on the healing process would be 
dependent on the molecular context of FNIII EDA’s position within the FN chain. Hence, 
we also tested the natural sequence FNIII 9-10-11-EDA-12-13-14 (Fig. 1) as well as the 
cleaved form FNIII 11-EDA + FNIII 12-13-14. 
 
4.3 Results 
4.3.1 Detection of GF and cytokines binding to FNIII 11-EDA 
The capacity of FNIII 11-EDA to bind a wide panel of GFs and cytokines was 
assessed by ELISA (Fig. 2a). ELISA plates were coated with GFs and cytokines and 
incubated with FNIII 11-EDA. Bound FNIII 11-EDA was then detected with an anti-FNIII 
EDA antibody followed by an HRP-conjugated secondary antibody. Among all GFs and 
cytokines tested only placenta growth factor-2 (PlGF-2), PDGF-AA, PDGF-BB, stromal 
cell-derived factor-γ (CXCL12-γ or SDF-1 γ) and BMP-2 showed significant binding. 
PDGF-AA (A450nm > 0.8) and CXCL12-γ (A450nm > 0.6) in particular showed strong binding 
to FNIII 11-EDA.  In order to verify that the observed binding was not due to FNIII 11 
we repeated the experiment using FNIII EDA and tested its ability to bind PlGF-2, PDGF-
AA, PDGF-BB, CXCL12-γ, BMP-2 and bovine serum albumin (BSA) as control. The 
binding observed in that case (Fig. 2b) was equivalent to the one observed with FNIII 
11-EDA, thus confirming that the GFs and cytokines binding to FNIII 11-EDA does not 
depend on the presence of FNIII 11 domain. 
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Fig. 2. Binding of GFs and cytokines to FNIII 11-EDA and FNIII EDA. (a) GF and 
cytokine binding to FNIII 11-EDA measured by ELISA. Only PlGF-2, PDGF-AA, PDGF-BB, 
CXCL12-γ and BMP-2 showed significant binding to FNIII 11-EDA. (b) Binding of BSA, 
PlGF-2, PDGF-AA, PDGF-BB, CXCL12-γ and BMP-2 to FNIII EDA measured by ELISA. 
Bars represent mean ± SEM (n=3) from two independent experiments. *** P< 0.001; 
comparison to BSA. 
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4.3.2 FNIII 11-EDA and PDGF-AA stimulate fibroblast proliferation 
and differentiation 
We sought to understand whether the binding of PDGF-AA to FNIII 11-EDA could 
modulate its biological activity. PDGF-AA being known to stimulate fibroblast 
proliferation23–25, we cultured 3T3 fibroblasts in normal media or in presence of FNIII 
11-EDA or PDGF-AA or both and after 4 days cell proliferation was measured using 
alamarBlue (Fig. 3a) and cells were stained to assess differentiation by flow cytometry 
(Fig. 3b). Here FNIII 11-EDA alone did not stimulate fibroblast proliferation and PDGF-
AA only marginally induced proliferation compared to the untreated control (Fig. 3a). 
However combination of both FNIII 11-EDA and PDGF-AA together significantly 
stimulated cell proliferation compared to the control although this effect was not 
statistically different to the one obtained using PDGF-AA alone (Fig. 3a). Furthermore, 
PDGF-AA and FNIII EDA have been reported to drive fibroblast differentiation to 
myofibroblasts12,26, thus we observed whether the FNIII 11-EDA-PDGF-AA complex 
could enhance differentiation along with the proliferation. Differentiation of fibroblasts 
to myofibroblasts being characterized by expression of alpha-smooth muscle actin (α-
SMA)27, thus we stained the cells and measured their expression of α-SMA by flow 
cytometry (Fig. 3b). While only a marginal increase in α-SMA expression was observed 
upon stimulation with FNIII 11-EDA or PDGF-AA, the combination of both led to a 
significant increase in the expression of α-SMA compared to the untreated control 
group.  
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Fig. 3. FNIII 11-EDA and PDGF-AA induce fibroblast proliferation and 
differentiation. (a) Fibroblasts proliferation upon stimulation with FNIII 11-EDA and 
PDGF-AA.  Fibroblasts were cultured in presence of FNIII 11-EDA or PDGF-AA or both. 
After 4 days cell proliferation was measured using alamarBlue.  FNIII 11-EDA and PDGF-
AA together significantly stimulated fibroblast proliferation. (b) Fibroblast 
differentiation to myofibroblasts upon stimulation with FNIII 11-EDA and PDGF-AA was 
evaluated by flow cytometry. Combination of FNIII 11-EDA and PDGF-AA induced 
differentiation of fibroblasts as shown by the mean fluorescence intensity (MFI) of α-
SMA intracellular staining. Bars represent mean ± SEM. Box plots represent means ± 
95% confidence interval (n = 4) from a single experiment. * P< 0.05; ns, not significant. 
 
4.3.3 Fibrin matrices functionalized with FNIII 11-EDA-containing 
fibronectin fragments delay skin wound healing 
We then explored whether the presence of FNIII 11-EDA at wound sites would 
influence the healing process and if this effect was dependent on the molecular context 
of FNIII 11-EDA. FNIII 11-EDA being naturally present in the ECM, we decided to 
incorporate the fragments bound in matrix to mimic the in vivo situation. Here, as a 
matrix model, we used a fibrin hydrogel with a volume of 80 µL and a concentration of 
10 mg/mL of fibrinogen. To be incorporated in the matrix, the FN fragments were 
designed to contain a transglutaminase substrate sequence derived from α2-plasmin 
inhibitor (NQEQVSPL, denoted herein TG) at the N-terminus. Therefore, the FN 
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fragments were covalently incorporated in the matrix through the transglutaminase 
activity of factor XIIIa during fibrin polymerization28. To determine whether the 
molecular context of FNIII 11-EDA could modulate its effect on wound closure, we also 
tested fibrin matrix compositions containing either FNIII 9-10-11-EDA-12-13-14 which 
is the natural FN chain within which FNIII EDA is located, or with FNIII 11-EDA and FNIII 
12-13-14 as separate molecules, which occurs upon cleavage by elastase 2 secreted by 
neutrophils, releasing the immunological activity of FNIII 11-EDA22. In order to 
determine whether any observed effect by the matrices functionalized with FN 
fragments was due to TLR4 agonization, fibrin matrices loaded with an amount of LPS 
corresponding to the level of TLR4 activation by the dose FNIII 11-EDA22 used in the 
other matrices were also tested. 
Full-thickness back-skin wounds were treated with the fibrin matrices and wound 
histology was analyzed after 7 days. Interestingly wounds that received fibrin matrices 
containing any forms of FNIII 11-EDA all showed a delay in re-epithelization, reaching 
statistical significance in the case of FNIII 11-EDA + FNIII 12-13-14 (Fig. 4a). However, 
observation of the granulation tissue area showed statistical equivalence among all 
groups (Fig. 4b) although the matrices containing only fibrin induced slightly larger 
granulation area than any other group. Surprisingly fibrin matrices loaded with LPS 
yielded the smallest granulation area. Representative wound histology for all groups 
are shown in Fig. 4c. 
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Fig. 4. Treatment of skin wounds with fibrin matrices functionalized with FNIII 
11-EDA + FNIII 12-13-14 delays re-epithelization. Full-thickness back-skin wounds 
(6 mm in diameter) were treated with fibrin matrices functionalized with fibronectin 
fragments. After 7 days wound closure (a) and granulation tissue (b) formation were 
evaluated by histology. (c) Representative histology at 7 days (hematoxylin and eosin 
staining). Dashed lines indicate wound edges; black arrows indicate tips of the healing 
epithelium tongue. Bars represent mean ± SEM. (n = 4-6) from a single experiment. * 
P< 0.05; ns, not significant.  
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4.4 Discussion 
Although expression of FNIII EDA is essential for embryonic development29 some 
of its functions are not yet fully understood. A splice variant of FN, FNIII EDA is 
expressed during embryogenesis2,3 and later upon tissue damages9,10 or within 
tumors4,5 and chronic inflammation6–8 sites. Furthermore many recent studies 
regarding FNIII EDA explored its ability to agonize TLR4 and sustain inflammation22,30 
or drive fibrosis31. However, although the interactions between many domains of FN, 
including FNIII EDA’s neighboring domain FNIII 12-13-14, and GFs and cytokines are 
well documented15,16,20,32, the ability of FNIII EDA to bind signaling molecules remains 
mostly unexplored. FNIII EDA also actively modulates the healing process18 at sites of 
injury as shown by abnormal skin wound healing in FNIII EDA-/- mice19, however its 
precise role within the healing process remains poorly understood.  
We showed in a previous study the cryptic nature of FNIII EDA22, its ability to 
agonize TLR4 being enhanced upon cleavage of FN by elastase 2. In the same study 
we showed that although the C-terminus of FNIII EDA can be exposed by proteolysis, 
no evidence suggests that an N-terminally exposed FNIII EDA can occur in vivo. 
Furthermore, we showed that N-terminal extension of FNIII EDA with FNIII 11 is 
necessary in order to retain its full ability to agonize TLR4. For these reason FNIII 11-
EDA was used in place of FNIII EDA in the present study. 
Due to FNIII EDA’s placement within the FN chain (Fig. 1) next to the GF-binding 
domain FNIII 12-13-14 in addition to its expression in GF- and cytokine-rich 
microenvironments17,  we hypothesized that FNIII EDA could bind and modulate the 
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activity of bound signaling proteins upon FN splicing. Here we tested the binding of 
multiple GFs and cytokines to FNIII 11-EDA (Fig. 2a) and FNIII EDA (Fig. 2b), with PlGF-
2, PDGF-AA, PDGF-BB, CXCL12-γ and BMP-2 showing significant binding. Surprisingly, 
although the number of GFs binding FNIII 11-EDA is limited, these GFs come from three 
different families, the vascular endothelial growth factor (VEGF) family (PlGF-2), the 
PDGF family (PDGF-AA, PDGF-BB) and the transforming growth factor β (TGF-β) family 
(BMP-2). CXCL12-γ is a chemokine located in the heart and brain associated with 
chronic inflammation33.  
The strong binding to PDGF-AA is particularly intriguing. Indeed, although FN 
devoid of FNIII EDA already showed the ability to bind these four GFs, PDGF-AA 
showed the lowest affinity for FN32. We sought to investigate whether FNIII 11-EDA 
could modulate the activity of PDGF-AA on fibroblasts proliferation and differentiation 
to myofibroblasts. Although PDGF-AA is a known mitogen for fibroblast23–25, it was not 
able in our case to stimulate a significant fibroblast proliferation in vitro on its own (Fig. 
3a). The FNIII 11-EDA-PDGF-AA complex however did significantly stimulate fibroblast 
proliferation compared to the untreated control (Fig. 3a). Furthermore, when used 
alone both FNIII 11-EDA and PDGF-AA marginally induced fibroblast differentiation to 
myofibroblasts, whereas the FNIII 11-EDA-PDGF-AA complex was able to drive 
significant differentiation as shown by the increased expression of α-SMA (Fig. 3b). 
These results suggest that FNIII 11-EDA modulates the effect of PDGF-AA on fibroblast 
proliferation and differentiation, although the lack of statistical significance between 
the effect of PDGF-AA alone and the FNIII 11-EDA-PDGF-AA complex keeps the door 
open to the possibility that the observed effect could be merely the additive effect of 
FNIII 11-EDA and PDGF-AA. Furthermore, fibroblast 3T3 being relatively fast to 
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proliferate, slow growing primary fibroblasts might be a better option to repeat this 
experiment. 
Interestingly, the PDGF-AA-driven fibroblast to myofibroblasts differentiation has 
been reported to be a promoter of wound closure26. Moreover lack of FNIII EDA leads 
to abnormal wound healing as shown in FNIII EDA-/- mice19, suggesting that FNIII EDA 
actively modulates the healing process18 although its precise function during tissue 
repair remains unknown. Thus, in order to better characterize the effect of FNIII EDA 
on wound closure, we used a skin wound model in which wounds were treated with 
functionalized fibrin matrices creating a microenvironment rich in FNIII EDA-containing 
FN fragments. Here, in order to assess whether the any observed effect would be 
proteolysis-dependent22, we compared fibrin matrices functionalized with FNIII 11-EDA 
to matrices functionalized with the longer natural sequence FNIII 9-10-11-EDA-12-13-
14 or with the cleaved form FNIII 11-EDA and FNIII 12-13-14 on different molecules. 
Surprisingly after 7 days all FNIII EDA-containing fibrin matrices compositions impaired 
re-epithelization to some extent compared to matrices containing only fibrin (Fig. 4a,c) 
although this effect was greater with FNIII 11-EDA and FNIII 12-13-14 on separate 
molecules. Interestingly LPS-containing fibrin matrices did not influence re-
epithelization, suggesting that that the effect observed with FNIII EDA-containing 
matrices is likely not due to TLR4 agonization. Moreover, all matrices compositions 
slightly reduced the granulation tissue area (Fig. 4b,c). These surprising results suggest 
that an FNIII 11-EDA-rich microenvironment impairs wound healing and that this effect 
is accentuated upon FN cleavage by elastase 2. However, these results should be 
interpreted with caution given that only one endpoint was used for the experiment. As 
FNIII EDA is induced by TGF-β134, which reaches maximum expression 72h post-
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wounding35, it would be also of interest to include different timepoints for the 
beginning of the treatments. Furthermore, the natural wound healing process involves 
the formation of fibrin-plasma fibronectin matrix immediately after injury36, with FNIII 
EDA-containing fibronectin appearing only after 2 days. This could suggest that FNIII 
EDA would be beneficial to the healing process only when applied on the wound after 
a couple days. 
In conclusion, we showed that FNIII EDA is yet another GF binding domain of FN, 
with an especially strong affinity for PDGF-AA. FNIII 11-EDA and PDGF-AA showed the 
ability to enhance fibroblasts proliferation and differentiation into myofibroblasts 
although more experiment are required to further investigate a potential synergy 
between these proteins. Fibrin matrices functionalized with variants of FNIII 11-EDA 
had surprisingly negative effect on wound closure, however here again more 
experiment will be required to precisely characterize how FNIII EDA affects tissue repair. 
In that regard, it would be of special interest to explore how PDGF-AA delivered in a 
FNIII 11-EDA-containing fibrin gel would influence wound healing. 
 
4.5 Methods 
4.5.1 Recombinant proteins  
Fibronectin fragments were engineered to bear at their N-terminus the 
coagulation transglutaminase Factor XIIIa peptide substrate NQEQVSPL (TG) and were 
cloned in a pET-22b (+) (Novagen) plasmid between the restriction sites NdeI and NotI. 
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This plasmid contains a 6xHis-tag being added at the 3’ end of the inserted genes. E. 
coli BL21DE3 were transformed and used for protein production. The recombinant 
proteins were purified using a HIStrap column (GE Healthcare) and washed using 0.1 
% Triton X-100 in PBS for LPS removal and an ATP solution (2 mM ATP, 50 mM Tris-
HCl, 10 mM MgSO4, pH 7.4) for DnaK removal. An imidazole (1 M) buffer was used for 
elution. The proteins were then stored in TBS pH 7.4 at -80°C. Endotoxin levels were 
tested by Quantitative Chromogenic Limulus Amebocyte Lysate and were below 0.2 
EU/µg. 
 
4.5.2 Growth factors and cytokines 
All GFs were purchased in their mature forms, highly pure (> 95% pure), carrier 
free and lyophilized. PDGF-DD, and BMP-2 were purchased from R&D Systems. FGF-2 
were purchased from Invitrogen. CCL21, CXCL10, CXCL11, CXCL12-γ, FGF-1, FGF-18, 
BMP-7, TGF-β1, TGF-β2, TGF-β3, EGF, IL-2, IL-4, IL-5, IL-7, IL-8, IL-10, IL-12, PDGF-AA, 
PDGF-AB, PDGFCC, PlGF-1, PlGF-2, IGF-2, NGF and NT-3 were purchased from 
PeproTech EC Ltd. Except TGF-β1, TGF-β2, TGF-β3, BMP-2, BMP-6 and BMP-7 that have 
been produced in eukaryotic cells, the other GFs were produced in E. coli and therefore 
were not glycosylated. All GFs were reconstituted and stored according to the 
provider’s instructions, in order to regain full activity and no loss of protein. 
 
4.5.3 Detection of GF and cytokine binding to FNIII 11-EDA 
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ELISA plates (Nunc MaxiSorp, Thermo Fisher Scientific) were coated with 50 nM 
GFs (in PBS, 1 h at 37°C) and blocked with 2 % bovine serum albumin (BSA) in 
phosphate buffer saline (PBS) with 0.05 % Tween 20 (PBS-T) for 1 h at RT. Then, wells 
were washed with PBS-T and further incubated with 10 nM of FNIII 11-EDA in PBS-T 
with 0.1 % BSA; 45 min at RT. After 3 washes with PBS-T, wells were incubated for 45 
min at RT with anti-FNIII EDA (abcam, IST-9) antibody followed by an HRP-conjugated 
goat anti-mouse IgG1 secondary antibody (SouthernBiotech). After washes, antibody 
was detected with tetramethylbenzidine substrate by measurement of the absorbance 
at 450 nm. 
 
4.5.4 Proliferation of fibroblasts 
Swiss 3T3 fibroblasts were plated at 104 per well in 24-well plates containing 
DMEM medium with 10 % FBS and incubated for 4 days with 150 ng/mL FNIII 11-EDA 
or 100 ng/mL PDGF-AA or both. On day 4 alamarBlue (ThermoFisher scientific) was 
added to the media according to manufacturer’s recommendations followed by 
incubation for 3 h. 100 µl of the media was then transferred to a 96-well plate and 
fibroblast proliferation was measured by light absorption at 570 nm. 
 
4.5.5 Flow cytometry 
Flow cytometry measurements were performed using a CyAn ADP Analyzer 
(Beckman Coulter) and data were analyzed using FlowJo software. Viable cells were 
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detected by LIVE/DEAD (L/D) Fixable Aqua stain (Invitrogen) and an anti- α-SMA FITC 
(abcam) antibody was used for surface and intracellular staining. The following staining 
steps were performed on ice. Cells were washed with PBS, stained for 15 min with Aqua 
L/D stain, resuspended in PBS + 2 % FBS for surface staining for 15 min and finally fixed 
for 15 min in PBS + 2 % PFA. Intracellular staining was performed in PBS + 2 % FBS 
supplemented with 0.5 % saponin.  
 
4.5.6 Skin wound model 
C57BL/6 male mice were 10 to 12 weeks old at the beginning of the experiment. 
Their backs were shaved and two full-thickness punch-biopsy wounds (6 mm in 
diameter) were created in each mouse. Directly after, fibrin matrices (80 µl, 10 mg/ml 
fibrinogen, 2 U/ml of thrombin, 4 U/ml of factor XIII, 5 mM CaCl2) empty or containing 
1 nmol of FNIII 9-10-11-EDA-12-13-14 or FNIII 11-EDA with or without 1 nmol of FNIII 
12-14 or 200 ng of LPS were polymerized on the wounds. The wounds were then 
covered with adhesive film dressing (Hydrofilm, Hartmann). After 7 days, mice were 
sacrificed and the wounds were harvested for histological analysis. 
 
4.5.7 Histological analysis 
An area of 8 mm in diameter, which includes the complete epithelial margins, 
was excised. Wounds were cut on one edge and embedded. Histological analyses were 
performed on serial sections (4µm paraffin sections) until reaching the central portion 
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of the wound. The extent of re-epithelialization and granulation tissue formation was 
measured by histomorphometric analysis of tissue sections (H&E stain) using ImageJ 
software. For analysis of re-epithelialization: the distance that the epithelium had 
traveled across the wound was measured; the muscle edges of the panniculus carnosus 
were used as indicator for the wound edges; re-epithelialization was calculated as the 
percentage of the distance of edges of the panniculus carnosus muscle. For granulation 
tissue quantification: the area covered by a highly cellular tissue was determined in 
order to obtain the area at the center of the wound.  
 
4.5.8 Statistical Analysis 
Statistical analysis were performed using 1-way analysis of variance (ANOVA) and 
Bonferonni posttest using GraphPad Prism v.5. 
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The extracellular matrix (ECM) protein fibronectin (FN) is a remarkably polyvalent 
molecule essential for processes such as cell adhesion, migration, growth, and 
differentiation1. Nevertheless, some functions of FN are not yet understood. The 
alternatively spliced type III repeat extra domain A (FNIII EDA) shows the ability to 
stimulate the immune system through agonization of Toll-like receptor 4 (TLR4)2 and 
to modulate wound healing3. However, the exact physiological roles FNIII EDA carries 
out during these processes remain enigmatic. 
In chapter 2 of this thesis we revealed that the TLR4 agonizing potential of FNIII 
EDA is cryptic, becoming exposed by proteolytic cleavage by elastase 2, secreted by 
neutrophils, between FNIII EDA and FNIII 12. Moreover, we showed that the ability of 
FNIII EDA to trigger an antigen-specific immune response is enhanced when it is 
delivered in an ECM-like microenvironment, which correlates with the observation that 
FNIII EDA is usually expressed in the cellular form of FN. Furthermore, FNIII EDA and 
TLR4 activation contribute to the progression of diseases characterized by neutrophil 
infiltration such as psoriasis4 or scleroderma5.  Thus, the creation of strong TLR4-
agonizing microenvironment by neutrophil-derived elastase 2-mediated proteolysis of 
FN could be part of the underlying mechanism contributing to the progression of these 
pathologies. In addition, we showed, using two tumor growth models, the ability of 
ECM-bound FNIII EDA to induce a functional cytotoxic T lymphocyte response. Thus, 
these findings could contribute to the development of new anti-tumoral 
immunotherapy strategies, either by delivering ECM-bound FNIII EDA fragments in 
combination with antigens, or by inducing the elastase 2-dependent proteolysis of FN 
within the tumor, increasing the level of immunoactive FN.  
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In chapter 3 we demonstrated the ability of the N-terminally extended form of 
FNIII EDA, FNIII 11-EDA, to synergize with the TLR9 ligand CpG, leading to an enhanced 
activation of DCs. Interestingly, TLR synergies have been reported to rely heavily on 
simultaneous activation of the TRIF and MyD88 pathways6. TLR9 signals strictly through 
MyD88 while TLR4 can signal through both pathways. Thus, as FNIII EDA has previously 
been reported to signal through MyD887, this suggests that it also has the ability to 
activate the TRIF pathway. Moreover, this also suggests that FNIII EDA could have the 
capacity to synergize with many TLR ligands8. We then showed the ability of CpG and 
FNIII EDA to synergize in vivo using a tumor model and a chronic hepatitis B transgenic 
mouse model expressing a hepatitis B virus (HBV) transgene. Indeed, the combination 
of both TLR agonists displayed the ability to synergize to break T cell tolerance and 
induce an enhanced antigen specific response. These enhanced responses were 
achieved while lowering the total dose of CpG, thus lowering the risks of potential side 
effects. Hence, as multiple adjuvant therapies are required to achieve an efficient 
response against specific diseases9,10, combination of CpG and FNIII EDA might lead to 
the development of potent immunotherapies with fewer side effects and improved 
safety. Based on this, a potential development could involve intratumoral deliveries of 
CpG along with elastase 2, as previously mentioned, as this would create a multiple-
antigen multiple-adjuvant microenvironment. Although we showed in Chapter 2 that 
the efficacy of FNIII 11-EDA could be enhanced by a delivery in a fibrin matrix, the 
integration of CpG in such matrices represent a difficult challenge. Thus, in order to 
study the ability of FNIII 11-EDA and CpG to synergize with a minimum of variability, 
soluble formulations were chosen. However, future development should include the 
administration of both FNIII 11-EDA and CpG in an ECM analog.  
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Finally, in chapter 4 we revealed that FNIII EDA is a growth factor (GF) binding 
domain of FN. All GFs that tested positive for binding to FNIII EDA and FNIII 11-EDA 
were already known binders of FN11, with PDGF-AA being the weakest one. However, 
here PDGF-AA displayed the strongest binding to FNIII EDA. We demonstrated that 
FNIII 11-EDA and PDGF-AA have together the ability to enhance fibroblasts 
proliferation and differentiation into myofibroblasts in comparison to PDGF-AA alone. 
However, as our results barely reached statistical significance, further investigation 
would be required to validate that point. PDGF-AA-driven fibroblast to myofibroblasts 
differentiation has been reported to promote tissue repair upon wound infiltration12 
while FNIII EDA-/- mice presented abnormal wound closure3. We thus hypothesized that 
fibrin gels functionalized with FNIII 11-EDA would accelerate wound healing through 
interaction with PDGF-AA and possibly other GFs. However, the FNIII 11-EDA-
containing-ECM analogs surprisingly delayed wound closure. This effect is likely not 
due to the pro-inflammatory properties of FNIII 11-EDA as LPS-containing fibrin 
matrices did not influence re-epithelization. Furthermore, excessive GF sequestration 
rendering them unable to promote wound healing is also unlikely as fibrin gels 
containing the GF binding domain FNIII 12-13-1413,14 are not reported to impair wound 
closure. Larger sample sizes and additional experiment end points, would be required 
to precisely characterize how FNIII EDA affects tissue repair.  
In conclusion, this thesis brings insight into the immunological, and to some 
extent regenerative, functions of FNIII EDA. Moreover, the link we expose between 
elastase 2 secretion by neutrophils and TLR4 agonization might help to better 
understand the progression of diseases such as scleroderma and psoriasis. 
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Furthermore, our results can present interesting novel options for the development of 
potent adjuvant formulations for immunotherapies with fewer side effects. 
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